

Article

Synthesis and Characterization of Novel Methyl (3)5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates

Gita Matulevičiūtė^{1,2}, Eglė Arbačiauskienė^{2,*} , Neringa Kleizienė¹, Vilija Kederienė², Greta Ragaitė¹, Miglė Dagilienė¹, Aurimas Bieliauskas¹, Vaida Milišiūnaitė¹, Frank A. Sløk³ and Algirdas Šačkus^{1,*}

¹ Institute of Synthetic Chemistry, Kaunas University of Technology, K. Baršausko g. 59, LT-51423 Kaunas, Lithuania; gita.matuleviciute@ktu.lt (G.M.); neringa.kleiziene@ktu.lt (N.K.); greta.ragaitė@ktu.lt (G.R.); migle.dagilienne@ktu.lt (M.D.); aurimas.bieliauskas@ktu.lt (A.B.); vaida.milisiunaite@ktu.lt (V.M.)

² Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, LT-50254 Kaunas, Lithuania; vilija.kederiene@ktu.lt

³ Vipergen ApS, Gammel Kongevej 23A, V DK-1610 Copenhagen, Denmark; fas@vipergen.com

* Correspondence: egle.arbačiauskienė@ktu.lt (E.A.); algirdas.sackus@ktu.lt (A.Š.); Tel.: +370-37-451-401 (A.Š.)

Abstract: Series of methyl 3- and 5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates were developed and regioselectively synthesized as novel heterocyclic amino acids in their *N*-Boc protected ester form for achiral and chiral building blocks. In the first stage of the synthesis, piperidine-4-carboxylic acid and (*R*)- and (*S*)-piperidine-3-carboxylic acids were converted to the corresponding β -keto esters, which were then treated with *N,N*-dimethylformamide dimethyl acetal. The subsequent reaction of β -enamine diketones with various *N*-mono-substituted hydrazines afforded the target 5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates as major products, and tautomeric NH-pyrazoles prepared from hydrazine hydrate were further *N*-alkylated with alkyl halides to give 3-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates. The structures of the novel heterocyclic compounds were confirmed by ¹H-, ¹³C-, and ¹⁵N-NMR spectroscopy and HRMS investigation.

Keywords: heterocyclic amino acids; pyrazoles; piperidines; β -keto esters; enamines; hydrazines; building blocks



Citation: Matulevičiūtė, G.; Arbačiauskienė, E.; Kleizienė, N.; Kederienė, V.; Ragaitė, G.; Dagilienė, M.; Bieliauskas, A.; Milišiūnaitė, V.; Sløk, F.A.; Šačkus, A. Synthesis and Characterization of Novel Methyl (3)5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates. *Molecules* **2021**, *26*, 3808. <https://doi.org/10.3390/molecules26133808>

Academic Editor: Mohammad Alam

Received: 17 May 2021

Accepted: 19 June 2021

Published: 22 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Heterocyclic amino acids are becoming very important in modern drug discovery [1–5]. For instance, (*RS*)-piperidine-3-carboxylic acid (*DL*-nipecotic acid) is one of the most potent inhibitors of neuronal and glial γ -aminobutyric acid (GABA) uptake in vitro [6]. (*S*)-Pyrrolidinyl-2-carboxylic acid (*L*-proline) has been found to act as an agonist of the glycine receptor and of both the *N*-methyl-*D*-aspartate (NMDA) and non-NMDA ionotropic glutamate receptors [7].

Heterocyclic amino acids are also important scaffolds and building blocks for the preparation of heterocyclic systems, hybrids, and peptides [8–11]. For example, *L*-proline has been applied as a scaffold in the preparation of pyrrolizidine [12–14], pyrrolo[1,2-*c*][1,3]oxazole [15], pyrrolo[2,1-*c*][1,4]benzodiazepine [16], and benzo[*f*]pyrrolo[1,2-*a*][1,4]diazepine derivatives [17], while nipecotic and isonipecotic acids have given derivatives of heterospirocyclic 3-amino-2*H*-azirines [18,19]. Moreover, *L*-proline is a building block for *N*-(3-mercapto-2-*D*-methylpropanoyl)-*L*-proline, named captopril, which is used to regulate blood pressure [20]. *D*-Nipecotic acid, a building block for (*R*)-1-[4,4-bis-(3-methyl-2-thienyl)-3-butenyl]-3-piperidine carboxylic acid, named (*R*)-tiagabine, which amplifies neurotransmission of GABA, the predominant inhibitory neurotransmitter in the brain [21–23]. New derivatives of nipecotic acid, guvacin, and homo- β -proline are very potent and selective analogs of GABA uptake inhibitors [24–26].

The heterocyclic tripeptide Gly-Pro-Glu I, containing an *L*-proline residue, is a neuroprotective compound for the control of neurodegenerative processes such as Parkinson's

disease [27,28], while a proline peptidomimetic, faldaprevir **II**, was used as an experimental drug to treat hepatitis (Figure 1) [29–31]. The synthetically prepared derivative of the tripeptide (pyro)Glu-His-Pro(NH₂) **III** has specific activity as a hypothalamic gland thyrotropin-releasing hormone [32]. Many aromatic heterocyclic amino acids, such as [5-amino-4-(*tert*-butoxycarbonyl)thiophen-2-yl]acetic acid, provide synthetic peptides, including enantiopure cyclic tetraamide **IV** [33], which are similar to compounds in marine plants that exhibit resistance to infection or antitumor effects [34].




Figure 1. Examples of biologically active peptides derived from heterocyclic amino acids: Gly-Pro-Glu **I**, faldaprevir **II**, (pyro)Glu-His-Pro(NH₂) **III**, cyclic tetraamide **IV**, and VPC00628 **V**.

Heterocyclic amino acids have been applied widely as building blocks for the preparation of DNA-encoded chemical libraries, including heterocyclic hybrid and peptide compounds [35–39]. In general, a DNA-encoded library of target component molecules should have a high degree of structural and functional diversity, taking into account diversity-oriented synthesis (DOS) [40]. For example, a highly specific and potent p38 α kinase tripeptide-type inhibitor (VPC00628) **V** containing the residue of 3-amino-1-phenyl-1*H*-pyrazole-4-carboxylic acid has been identified directly from a multimillion-membered DNA-encoded molecule library that was prepared using high-fidelity yoctoReactor (yR) technology [41].


We recently reported an efficient protocol for synthesizing highly functionalized amino acid building blocks by combining pyrazole, indazole, and indole carboxylates with *N*-Boc-3-iodoazetidene [42]. Moreover, we synthesized 4-(*N*-Boc-cycloaminy)-1,3-thiazole- and 4-(*N*-Boc-cycloaminy)-1,3-selenazole-5-carboxylates as novel heterocyclic chiral amino acid-like derivatives [43,44]. Herein, we report the efficient synthesis of 3(5)-(N-Boc-piperidiny)-1*H*-pyrazole-4-carboxylates as heterocyclic amino acid-like derivatives for novel achiral and chiral building blocks from piperidine-4-carboxylic and (*R*)- and (*S*)-piperidine-3-carboxylic acids.

2. Results and Discussion


Numerous methods for forming pyrazole ring systems have been developed. The most common synthetic method for the production of pyrazoles is the condensation of the corresponding hydrazine derivative, which acts as a double nitrogen nucleophile, with three carbon units containing compounds such as 1,3-dicarbonyl and 2,3-unsaturated carbonyl, or enamine [45–47]. Rosa et al. [48] developed a simple and efficient method for preparing both regioisomers of 4,5-substituted *N*-phenylpyrazoles from β -enamino diketones and phenylhydrazine, and the regiochemistry of the reaction was protic or aprotic solvent depen-

dent. A patent [49] was obtained for the synthesis of 4-(piperidin-4-yl)-*N*-phenylpyrazole derivatives from β -enamino diketones with 4-fluoro- and 4-methoxyphenylhydrazines.

Our strategy for the synthesis of methyl 3(5)-(N-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates according to the enamine method is described in Schemes 1 and 2, and Figure 2. The synthetic sequence started with preparing β -keto esters **2a–c** by treating *N*-Boc protected piperidine acids **1a–c** with 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) and 4-dimethylaminopyridine (DMAP), and further methanolysis of Meldrum's acid adduct [50,51]. Compounds **2a–c** were treated with *N,N*-dimethylformamide dimethyl acetal (DMF·DMA) to obtain β -enamino diketones **3a–c** [49].



Scheme 1. Synthesis of starting β -enamino diketones **3a–c**.



4, 4', 5, 6: a R = *N*-Boc-piperidin-4-yl, R¹ = Ph; **b** R = *N*-Boc-piperidin-4-yl, R¹ = 4-MePh; **c** R = *N*-Boc-piperidin-4-yl, R¹ = 3-MePh; **d** R = *N*-Boc-piperidin-4-yl, R¹ = 3-FPh; **e** R = *N*-Boc-piperidin-4-yl, R¹ = 2-FPh; **f** R = *N*-Boc-piperidin-4-yl, R¹ = 4-OMePh; **g** R = *N*-Boc-piperidin-4-yl, R¹ = 3-OMePh; **h**: R = *N*-Boc-piperidin-4-yl, R¹ = 3-CF₃Ph; **i** R = *N*-Boc-piperidin-4-yl, R¹ = Me; **j** R = (3*R*)-*N*-Boc-piperidin-3-yl, R¹ = Ph; **k** R = (3*S*)-*N*-Boc-piperidin-3-yl, R¹ = Ph; **l** R = (3*R*)-*N*-Boc-piperidin-3-yl, R¹ = 4-MePh; **m** R = (3*S*)-*N*-Boc-piperidin-3-yl, R¹ = 4-MePh; **n** R = (3*R*)-*N*-Boc-piperidin-3-yl, R¹ = 3-CF₃Ph; **o** R = (3*S*)-*N*-Boc-piperidin-3-yl, R¹ = 3-CF₃Ph.

Scheme 2. Synthesis of compounds **5a–o** and **6a–o**.

In the next step, we investigated the formation of 3(5)-substituted-1*H*-pyrazoles **5** and **6** via the key intermediates **4** and **4'** (Scheme 2). Optimization of the coupling reaction conditions was undertaken, choosing **3a** and phenylhydrazine as a model system (Table 1). An investigation of the reaction course and regioselectivity was carried out in various solvents, and the LC/MS and ¹H-NMR spectral data of the crude reaction mixture of intermediate compound **4a** and products **5a**, **6a** were analyzed after 1 and 18 h (Table 1). EtOH was used as a polar protic (Table 1, entry 1), ACN as a polar aprotic (Table 1, entry 2), and CCl₄ as a nonpolar solvent (Table 1, entry 3). As a result, the reaction in EtOH provided high regioselectivity (99.5%) and good yield (78%) of **5a** and just traces of its regioisomer **6a** (Table 1, entry 1). Similarly, the reaction in ACN resulted in **5a** as the main product (75%), and **6a** was obtained with a 3% yield (Table 1, entry 2). The poorest yield and regioselectivity

were observed when the reaction mixture was stirred in CCl_4 . In this case, **5a** formed as a major product with 54% yield, and regioisomer **6a** was obtained with 9% yield (Table 1, entry 3). During optimization of the reaction conditions in different solvents, $^1\text{H-NMR}$ analysis of the crude reaction mixture after 1 h also showed the formation of intermediate compound **4a**, which was successfully isolated for structure elucidation. The regioisomer **6a** formed as a minor isomer via intermediate **4'a** which resulted from the nucleophilic attack of a secondary amino group of phenylhydrazine on β -enamino diketone **3a**.




Figure 2. Synthesized compounds **5a–o**.

Table 1. Solvent effect on the formation of compounds **4a**, **5a**, and **6a**.

Entry	Solvent *	t (h)	4a/5a/6a **	t (h)	4a/5a/6a **	5a, Yield (%) ***
1	EtOH	1	52.4/46.8/0.8	18	0/99.5/0.5	78
2	ACN	1	27.6/68.2/4.2	18	0/95.2/4.8	75
3	CCl_4	1	58.3/27.5/14.2	18	18.3/67.9/13.8	54

* All reaction mixtures were stirred at room temperature. ** Ratio was determined by $^1\text{H-NMR}$ spectral data from crude sample. *** After purification by column chromatography.

In the case of intermediate compound **4a**, the key information for structure elucidation was obtained from the $^{15}\text{N-NMR}$ data. In the $^1\text{H-}^{15}\text{N}$ HMBC spectrum of **4a**, the ^{15}N shift of $\delta -241.2$ ppm was assigned to nitrogen N_a , due to the correlation with the neighboring protons $2'(6')\text{-H}$ ($\delta 6.81$ ppm) from the phenyl moiety (Figure 3). The $^1\text{H-}^{15}\text{N}$ HSQC experiment indicated that proton $\text{N}_a\text{-H}$ ($\delta 6.24$ ppm) had one-bond connectivity with the aforementioned nitrogen N_a at $\delta -241.2$ ppm, while proton $\text{N}_b\text{-H}$ ($\delta 11.72$ ppm) generated a cross peak with nitrogen N_b at $\delta -275.1$ ppm. The formation of compound **4a** was also confirmed by a NOESY experiment, which exhibited NOEs between the $2'(6')\text{-H}$ protons at $\delta 6.81$ ppm and the enamine proton at $\delta 8.28$ ppm. However, the configuration of the (*2E* or *2Z*)-isomer of compound **4a** is not yet known.

Discrimination between regioisomeric compounds **5a** and **6a** was based on data from $^1\text{H-}^{13}\text{C}$ HMBC, $^1\text{H-}^{15}\text{N}$ HMBC, and $^1\text{H-}^1\text{H}$ NOESY experiments (Figure 3). The $^1\text{H-}^{15}\text{N}$ HMBC experiment of the major regioisomer **5a** revealed three-bond correlations between the piperidine $4'\text{-H}$ proton at $\delta 3.10$ ppm and the phenyl group $2''(6'')\text{-H}$ protons

at δ 7.34 ppm, with the pyrazole N-1 “pyrrole-like” nitrogen at δ -160.3 ppm [52,53]. The ^1H - ^1H NOESY spectrum of **5a** exhibited NOEs between the phenyl group 2''(6'')-H protons and the 4'-H proton from the piperidine moiety.





Figure 3. Relevant ^1H - ^{13}C HMBC, ^1H - ^{15}N HMBC, ^1H - ^1H NOESY, and ^1H - ^{15}N HSQC correlations and ^1H -NMR (italics), ^{13}C -NMR, and ^{15}N -NMR (bold) chemical shifts of intermediate compounds **4a**, **5a** (major regioisomer), and **6a** (minor regioisomer).

The second regioisomer **6a** was easily identified by utilizing a similar approach. The minor regioisomer **6a** exhibited a strong three-bond connectivity between the piperidine proton 4'-H (δ 3.43 ppm) and the pyrazole N-2 “pyridine-like” nitrogen at δ -81.5 ppm, while the phenyl group protons 2''(6'')-H (δ 7.68 ppm) showed three-bond connectivity with the pyrazole N-1 “pyrrole-like” nitrogen at δ -165.7 ppm. Moreover, the pyrazole 5-H proton in the ^1H - ^{13}C HMBC spectrum showed a three-bond connectivity with the phenyl group C-1'' carbon at δ 139.3 ppm. Finally, confirmation of these regiochemical assignments was obtained from the ^1H - ^1H NOESY **6a** spectrum, showing only the NOEs between the phenyl group 2''(6'')-H protons and the pyrazole 5-H proton (δ 8.34 ppm).

The optimal conditions for the regioselective synthesis of methyl 5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylate **5a** were applied to the synthesis of other pyrazoles to evaluate the scope of the methodology (Figure 2). β -Enamino diketone **3a** was coupled with different phenylhydrazines to give corresponding products **5b–h** with fair to good yields. No obvious effect of the phenylhydrazine substituent on the reaction yield was observed. A reaction of β -enamino diketone **3a** with methylhydrazine provided a corresponding *tert*-butyl 4-[4-(methoxycarbonyl)-1-methyl-1*H*-pyrazol-5-yl]piperidine-1-carboxylate **5i** with a 51% yield. To our delight, the reactions of chiral β -enamino diketones **3b,c** with phenyl-, (4-methylphenyl)- or [3-(trifluoromethyl)phenyl]hydrazines formed products **5j–o**, also with good yields. While analyzing the LC/MS and ^1H -NMR spectral data of crude cyclization reaction mixtures, the formation of the regioisomeric **6b–o** was observed at trace amounts. The structure of compounds **5b–o** was determined by analogous NMR spectroscopy experiments as described above.

Next, having β -enamino diketone **3a**, we also performed a cyclocondensation reaction with hydrazine hydrate under the conditions described above, and the formation of

tautomeric 3(5)-substituted NH-pyrazole **7** was established by NMR analysis (Scheme 3, Figure 4).



Scheme 3. Two tautomers, **7a** and **7b**, of 3(5)-substituted NH-pyrazole (**7**) and regioisomers **5i**, **6i**, and compound **8**.




Figure 4. Relevant ¹H-¹³C HMBC, ¹H-¹⁵N HMBC, and ¹H-¹H NOESY correlations and ¹H-NMR (italics), ¹³C-NMR, and ¹⁵N-NMR (bold) chemical shifts of compound **7** (tautomeric equilibrium of **7a** and **7b**) and regioisomers **5i**, **6i** in CDCl₃ (25 °C).

The prototropic tautomerism of NH-pyrazoles is well documented in many scientific studies, including with the use of multinuclear dynamic NMR spectroscopy [54–56]. In general, the annular tautomerism of 3(5)-1H-pyrazoles in solution under normal conditions is a very rapid process on the NMR time scale, and the determination of tautomeric ratios can usually be achieved only at low temperatures [57]. We carried out NMR studies of compound **7** at 25 °C in a diluted CDCl₃ solution (Figure 4). The ¹H-NMR spectrum of compound **7** revealed a narrow singlet of the pyrazole ring proton resonating at δ 7.96 [3(5)-H] and two singlets for methyl ester and Boc moiety protons in the area of δ 3.83 (OCH₃) and 1.47 [C(CH₃)₃] ppm, respectively. The ¹³C-NMR spectrum provided important information; as expected, the characteristic signal of the pyrazole C-4 carbon at δ 110.1 ppm remained sharp, while the other two signals of pyrazole ring carbons 3(5)-C resonated at δ 138.7 and 153.6 ppm and appeared broadened. It is known that the broadening of NMR spectral lines very often reflects dynamic structural transformations of molecules in solution [58]. Therefore, the observed broadness of relevant C-3 and C-5 pyrazole carbon signals is due to the coalescence of individual signals to average signals, indicating tautomeric equilibrium of **7** (**7a** and **7b**). In addition, the pyrazole NH proton (δ 11.52 ppm) exhibited NOEs not only with the pyrazole ring proton at 7.96 ppm but also with the 3'-H piperidine protons at 1.70 ppm, which is only possible in the case of annular tautomerism **7**.

It was not possible to obtain relevant information for the nitrogen atoms of the pyrazole ring N-1 and N-2 from the ^{15}N -NMR spectral data since ^1H - ^{15}N HSQC and HMBC experiments showed no direct or long-range correlations with appropriate protons.

Tautomeric compound **7** was alkylated with alkyl iodides (Scheme 3). It is known that *N*-alkylation of asymmetrically ring-substituted *1H*-pyrazoles generally results in the formation of a mixture of regioisomeric *N*-substituted products [59]. Treatment of compound **7** with methyl iodide in the presence of KOH in DMF gave an inseparable mixture of regioisomers **5i** and **6i** in a ratio of about 1:5 and a total yield of 74%. However, alkylation of *1H*-pyrazole-4-carboxylate **7** with ethyl iodide under analogous conditions afforded compound **8** as the sole product with a good 87% yield.

Discrimination of regioisomeric compounds **5i** and **6i** were based on ^1H - ^{13}C HMBC, ^1H - ^{15}N HMBC, and ^1H - ^1H NOESY spectral data (Figure 4). In the ^1H - ^{15}N HMBC spectra of minor regioisomer **5i**, a ^{15}N shift of $\delta -178.3$ ppm was assigned to the “pyrrole-like” nitrogen N-1 due to the correlation of this signal with a piperidine ring proton 4'-H (δ 3.54 ppm). The ^1H - ^{13}C HMBC experiment exhibited a three-bond correlation of the 1-CH₃ protons with a pyrazole quaternary carbon C-5 at δ 148.7 ppm. Moreover, the ^1H - ^1H NOESY spectrum of **5i** exhibited NOEs between the methyl group protons (1-CH₃) at 3.92 ppm and the piperidine proton 4'-H at δ 3.54 ppm. In the ^1H - ^{15}N HMBC spectra of the major regioisomer **6i**, an appropriate correlation between the piperidine ring proton 4'-H (δ 3.36 ppm) and the “pyridine-like” pyrazole N-2 nitrogen which resonated at $\delta -77.3$ ppm could be observed. The ^1H - ^{13}C HMBC spectral data of compound **6i** provided a strong three-bond correlation of 1-CH₃ protons with pyrazole protonated carbon C-5 at δ 134.6 ppm. Finally, the regiochemistry of compound **6i** was confirmed by a NOESY experiment, which exhibited NOEs between the 1-CH₃ protons and pyrazole proton 5-H (δ 7.78 ppm). The structure of compound **8** was determined by analogous NMR spectroscopy experiments as described above.

After the successful synthesis of 3(5)-(N-Boc-piperidinyl)-*1H*-pyrazole-4-carboxylates, we further prepared several pyrazole carboxylic acids (Scheme 4). In particular, achiral pyrazole-4-carboxylic acid **9a** was prepared from the corresponding ester **5a** under the basic conditions (2N NaOH, methanol, reflux). The same hydrolysis conditions were applied to the production of chiral pyrazole-4-carboxylic acids (*R*)-**9b** and (*S*)-**9c** from esters **5j** and **5k**, respectively.

Pyrazole carboxylic acid amides, including anilides, have been known to play an important role in agrochemical research as fungicides [60,61]. Pyrazole-4-carboxylic acids **9a–c** were used to obtain new anilide compounds (Scheme 4). First, **9a** reacted with aniline in the presence of EDC·HCl, DMAP, and dichloromethane to give pyrazole anilide **10a**. Moreover, chiral pyrazole anilide (*R*)-**10b** (100% ee) was obtained from carboxylic acid **9b**, while the corresponding chiral anilide (*S*)-**10c** (96% ee) was synthesized from carboxylic acid **9c**. The enantiomeric purity of prepared anilides **10b,c** was evaluated by chiral HPLC analysis. As an example, HPLC analysis of enantiomeric samples of anilides **10b,c** is shown in Figure 5.





Figure 5. Chiral HPLC analysis of (a) anilide **10b** and (b) anilide **10c**. Conditions: CHIRAL ART Amylose-SA (100 × 4.6 mm I.D.; S-3 μm ; chiral selector amylose tris(3,5-dimethylphenylcarbamate); YMC); mobile phase: ACN/(H₂O + 0.1% HCOOH (30:70→70:30 in 10 min)); T = 36 °C; flow rate 1.0 mL/min.



Scheme 4. Reagents and conditions: (i) 2N NaOH, MeOH, reflux, 5 h; (ii) aniline, EDC-HCl, DMAP, DCM, 0 °C to r.t., 48 h.

3. Materials and Methods

3.1. General Information

All starting materials were purchased from commercial suppliers and were used as received. Flash column chromatography was performed on Silica Gel 60 Å (230–400 µm, Merck KGaA, Darmstadt, Germany). Thin-layer chromatography was carried out on Silica Gel plates (Merck Kieselgel 60 F₂₅₄) and visualized by UV light (254 nm). Melting points were determined on a Büchi M-565 melting point apparatus and were uncorrected. The IR spectra were recorded on a Bruker Vertex 70v FT-IR spectrometer (Bruker Optik GmbH, Ettlingen, Germany) using neat samples and are reported in the frequency of absorption (cm⁻¹). Mass spectra were obtained on a Shimadzu LCMS-2020 (ESI⁺) spectrometer (Shimadzu Corporation, Kyoto, Japan). High-resolution mass spectra were measured on Bruker MicrOTOF-Q III (ESI⁺) apparatus (Bruker Daltonik GmbH, Bremen, Germany). Optical rotation data were recorded on a UniPol L SCHMIDT+HAENSCH polarimeter (concentration of compound (g/100 mL) was included in calculations automatically (Windaus-Labortechnik GmbH & Co. KG, Clausthal-Zellerfeld, Germany). HPLC analysis was carried out on Shimadzu LC-2030C apparatus with CHIRAL ART Amylose-SA (100 × 4.6 mm I.D.; S-3 µm; chiral selector amylose tris(3,5-dimethylphenylcarbamate); YMC, Shimadzu USA Manufacturing, Inc., Canby, OR, USA). The ¹H-, ¹³C-, and ¹⁵N-NMR spectra were recorded in CDCl₃ solutions at 25 °C on a Bruker Avance III 700 (700 MHz for ¹H, 176 MHz for ¹³C, 71 MHz for ¹⁵N, Bruker BioSpin AG, Fallanden, Switzerland) spectrometer equipped with a 5 mm TCI ¹H-¹³C/¹⁵N/D z-gradient cryoprobe, and a Bruker Avance III 400 (400 MHz for ¹H, 101 MHz for ¹³C, 40 MHz for ¹⁵N, (Bruker BioSpin AG)

spectrometer using a 5 mm directly detecting BBO probe. The chemical shifts (δ) expressed in ppm, were relative to tetramethylsilane (TMS). The ^{15}N -NMR spectra were referenced to neat, external nitromethane (coaxial capillary). Full and unambiguous assignment of the ^1H -, ^{13}C - and ^{15}N -NMR resonances was achieved using a combination of standard NMR spectroscopic techniques [62] such as DEPT, COSY, gs-HSQC, gs-HMBC, NOESY and 1,1-ADEQUATE experiments [63]. ^1H -, ^{13}C -, and ^1H - ^{15}N HMBC NMR spectra, and HRMS data of all new compounds are provided in Supplementary Materials as Figures S1–S99.

3.2. Synthesis of *tert*-Butyl 3- and 4-[(2)-3-(Dimethylamino)-2-(methoxycarbonyl)prop-2-enoyl]piperidine-1-carboxylates (3a–c)

To a solution of the corresponding 1-(*tert*-butoxycarbonyl)piperidinecarboxylic acid (1a–c) (4 g, 17.4 mmol) in DCM (24 mL) cooled to 0 °C temperature Meldrum's acid (2.77 g, 19.2 mmol) was added followed by DMAP (4.26 g, 34.9 mmol). Then EDC·HCl (3.68 g, 19.2 mmol) was added in portions over 10 min. The reaction mixture was gradually warmed to r.t. and stirred for 16 h. The reaction solution was diluted with DCM (10 mL), washed with 1 M KHSO_4 (2 × 15 mL) and brine (20 mL). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Then the residue was dissolved in MeOH (20 mL) and left under reflux for 5 h. The solvent was evaporated in vacuo. A solution of crude β -keto ester (2a–c) (4.7 g, 16.4 mmol) and *N,N*-dimethylformamide dimethyl acetal (4.4 mL, 32.8 mmol) in dioxane (24 mL) was stirred at 100 °C. After 5 h the solvent was removed under reduced pressure. Crude compounds 3a–c were carried forward without any further purification.

3.3. Synthesis Procedure for the Preparation of Compounds 4a, 5a, and 6a

Method I. Compound 3a (500 mg, 1.5 mmol) was dissolved in EtOH (15 mL) and treated with phenylhydrazine (160 mg, 1.5 mmol). The reaction mixture was stirred at r.t. for 18 h. After removal of the solvent in vacuo, the residue was purified by flash column chromatography (SiO_2 , eluent: acetone/*n*-hexane, 1:7, *v/v*) to provide compound 5a (441 mg, 78%).

Method II. The reaction of compound 3a (500 mg, 1.5 mmol) with phenylhydrazine (160 mg, 1.5 mmol) in ACN (15 mL), was carried out and purified as described in Method I and afforded compounds 5a (424 mg, 75%) and 6a (17 mg, 3%).

Method III. The reaction of compound 3a (500 mg, 1.5 mmol) with phenylhydrazine (160 mg, 1.5 mmol) in CCl_4 (15 mL) was carried out as described in Method I, and the resulted residue was purified by gradient flash chromatography on silica gel (acetone/*n*-hexane, 1:15→1:7, *v/v*) to yield compounds 4a (79 mg, 14%), 5a (305 mg, 54%) and 6a (51 mg, 9%).

3.3.1. *tert*-Butyl 4-[(2*E*(*Z*))-2-(methoxycarbonyl)-3-(2-phenylhydrazinyl)prop-2-enoyl]piperidine-1-carboxylate (4a)

Yellowish oil. ^1H -NMR (700 MHz, CDCl_3): δ 1.46 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.53–1.60 (m, 2H, Pip 3,5-H), 1.75–1.83 (m, 2H, Pip 3,5-H), 2.76–2.87 (m, 2H, Pip 2,6-H), 3.70 (tt, $J = 11.7$ Hz, 3.5 Hz, 1H, Pip 4-H), 3.73 (s, 3H, OCH_3), 4.06–4.26 (m, 2H, Pip 2,6-H), 6.24 (s, 1H, N_aH), 6.81 (d, $J = 8.1$ Hz, 2H, Ph 2',6'-H), 6.99 (t, $J = 7.4$ Hz, 1H, Ph 4'-H), 7.28 (t, $J = 7.8$ Hz, 2H, Ph 3',5'-H), 8.28 (d, $J = 10.8$ Hz, 1H, 3*E*(*Z*)-H), 11.76 (d, $J = 10.8$ Hz, 1H, N_bH). ^{13}C -NMR (176 MHz, CDCl_3): δ 28.5 (2 × CH_2 , Pip 3,5-C and $\text{C}(\text{CH}_3)_3$), 43.8 (2 × CH_2 , Pip 2,6-C), 45.5 (Pip 4-C), 51.1 (OCH_3), 79.3 ($\text{C}(\text{CH}_3)_3$), 99.2 (2*E*(*Z*)-C), 113.6 (2 × CH, Ph 2',6'-C), 122.4 (Ph 4'-C), 129.5 (2 × CH, Ph 3',5'-C), 146.3 (Ph 1'-C), 154.8 ($\text{COOC}(\text{CH}_3)_3$), 162.4 (3*E*(*Z*)-C), 166.6 (COOCH_3), 203.5 (C=O). ^{15}N -NMR (71 MHz, CDCl_3): δ -275.1 (N_bH), -241.2 (N_aH). IR (FT-IR, ν_{max} , cm^{-1}): 3438(N-H), 2928, 1717 (C=O), 1690 (C=O), 1242, 767. MS *m/z* (%): 402 ($[\text{M} - \text{H}]^-$, 95%). HRMS (ESI⁺) for $\text{C}_{21}\text{H}_{29}\text{N}_3\text{NaO}_5$ ($[\text{M} + \text{Na}]^+$) calcd 426.1999, found 426.2001.

3.3.2. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-phenyl-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5a**)

Yellowish crystals, mp 151–153 °C. ¹H-NMR (700 MHz, CDCl₃): δ 1.46 (s, 9H, C(CH₃)₃), 1.53–1.61 (m, 2H, Pip 3,5-H), 2.28 (qd, *J* = 12.7 Hz, 4.5 Hz, 2H, Pip 3,5-H), 2.49–2.69 (m, 2H, Pip 2,6-H), 3.10 (tt, *J* = 12.4 Hz, 3.6 Hz, 1H, Pip 4-H), 3.84 (s, 3H, OCH₃), 4.02–4.27 (m, 2H, Pip 2,6-H), 7.31–7.37 (m, 2H, Ph 2,6-H), 7.47–7.54 (m, 3H, Ph 3,4,5-H), 8.03 (s, 1H, Pyr 3-H). ¹³C-NMR (176 MHz, CDCl₃): δ 28.4 (C(CH₃)₃), 28.6 (2 × CH₂, Pip 3,5-C), 35.1 (Pip 4-C), 44.1 (2 × CH₂, Pip 2,6-C), 51.2 (OCH₃), 79.4 (C(CH₃)₃), 111.7 (Pyr 4-C), 126.6 (2 × CH, Ph 2,6-C), 129.3 (2 × CH, Ph 3,5-C), 129.4 (Ph 4-C), 139.2 (Ph 1-C), 142.8 (Pyr 3-C), 149.8 (Pyr 5-C), 154.7 (COOC(CH₃)₃), 163.5 (COOCH₃). ¹⁵N-NMR (71 MHz, CDCl₃): δ −294.5 (N-Boc), −160.3 (Pyr N-1), −76.0 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{−1}): 2979, 1712 (C=O), 1674 (C=O), 1255, 765. MS *m/z* (%): 386 ([M + H]⁺, 99%). HRMS (ESI⁺) for C₂₁H₂₇N₃NaO₄ ([M + Na]⁺) calcd 408.1894, found 408.1894.

3.3.3. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-phenyl-1*H*-pyrazol-3-yl]piperidine-1-carboxylate (**6a**)

Brownish crystals, mp 134–136 °C. ¹H-NMR (700 MHz, CDCl₃): δ 1.47 (s, 9H, C(CH₃)₃), 1.83 (qd, *J* = 12.2 Hz, 4.2 Hz, 2H, Pip 3,5-H), 1.93–2.01 (m, 2H, Pip 3,5-H), 2.83–2.97 (m, 2H, Pip 2,6-H), 3.43 (tt, *J* = 11.6 Hz, 3.7 Hz, 1H, Pip 4-H), 3.85 (s, 3H, OCH₃), 4.12–4.29 (m, 2H, Pip 2,6-H), 7.30–7.35 (m, 1H, Ph 4-H), 7.43–7.49 (m, 2H, Ph 3,5-H), 7.65–7.70 (m, 2H, Ph 2,6-H), 8.34 (s, 1H, Pyr 5-H). ¹³C-NMR (176 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 31.0 (2 × CH₂, Pip 3,5-C), 35.0 (Pip 4-C), 44.0 (2 × CH₂, Pip 2,6-C), 51.4 (OCH₃), 79.4 (C(CH₃)₃), 112.8 (Pyr 4-C), 119.5 (2 × CH, Ph 2,6-C), 127.3 (Ph 4-C), 129.7 (2 × CH, Ph 3,5-C), 131.2 (Pyr 5-C), 139.3 (Ph 1-C), 155.0 (COOC(CH₃)₃), 159.0 (Pyr 3-C), 163.8 (COOCH₃). ¹⁵N-NMR (71 MHz, CDCl₃): δ −292.6 (N-Boc), −165.7 (Pyr N-1), −81.5 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{−1}): 2949, 1708 (C=O), 1692 (C=O), 1537, 753. MS *m/z* (%): 386 ([M + H]⁺, 95%). HRMS (ESI⁺) for C₂₁H₂₇N₃NaO₄ ([M + Na]⁺) calcd 408.1894, found 408.1894.

3.4. Synthesis of *tert*-Butyl 4-[4-(methoxycarbonyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylates (**5b–o**)

Compounds **5b–o** were obtained from β-enamino diketones **3a–c** (500 mg, 1.5 mmol) and appropriate hydrazines (1.5 mmol) in EtOH (15 mL) by the procedure which was used for the preparation of compound **5a** (Method I).

3.4.1. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-(4-methylphenyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5b**)

Compound **3a** was coupled with *p*-tolylhydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:7, *v/v*) to provide compound **5b** as yellowish crystals. Yield 411 mg (70%), mp 133–135 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.44 (s, 9H, C(CH₃)₃), 1.49–1.61 (m, 2H, Pip 3,5-H), 2.23 (qd, *J* = 12.6 Hz, 4.3 Hz, 2H, Pip 3,5-H), 2.44 (s, 3H, CH₃), 2.49–2.72 (m, 2H, Pip 2,6-H), 3.10 (tt, *J* = 12.4 Hz, 3.6 Hz, 1H, Pip 4-H), 3.83 (s, 3H, OCH₃), 4.00–4.29 (m, 2H, Pip 2,6-H), 7.17–7.23 (m, 2H, Ph 2,6-H), 7.27–7.32 (m, 2H, Ph 3,5-H), 8.00 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 21.4 (CH₃), 28.6 (C(CH₃)₃), 28.9 (2 × CH₂, Pip 3,5-C), 35.3 (Pip 4-C), 44.4 (2 × CH₂, Pip 2,6-C), 51.4 (OCH₃), 79.6 (C(CH₃)₃), 111.8 (Pyr 4-C), 126.5 (2 × CH, Ph 2,6-C), 130.0 (2 × CH, Ph 3,5-C), 137.0 (Ph 1-C), 139.7 (Ph 4-C), 142.9 (Pyr 3-C), 150.1 (Pyr 5-C), 155.0 (COOC(CH₃)₃), 163.8 (COOCH₃). ¹⁵N-NMR (41 MHz, CDCl₃): δ −294.5 (N-Boc), −160.6 (Pyr N-1), −75.8 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{−1}): 2980, 1703 (C=O), 1688 (C=O), 1255, 779. MS *m/z* (%): 400 ([M + H]⁺, 99%). HRMS (ESI⁺) for C₂₂H₂₉N₃NaO₄ ([M + Na]⁺) calcd 422.2050, found 422.2051.

3.4.2. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-(3-methylphenyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5c**)

Compound **3a** was coupled with *m*-tolylhydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:9, *v/v*) to provide compound **5c** as white crystals. Yield 310 mg (53%), mp 123–124 °C. ¹H-

NMR (400 MHz, CDCl₃): δ 1.45 (s, 9H, C(CH₃)₃), 1.51–1.60 (m, 2H, Pip 3,5-H), 2.26 (qd, J = 12.7 Hz, 4.4 Hz, 2H, Pip 3,5-H), 2.42 (s, 3H, CH₃), 2.50–2.71 (m, 2H, Pip 2,6-H), 3.08 (tt, J = 12.4 Hz, 3.6 Hz, 1H, Pip 4-H), 3.83 (s, 3H, OCH₃), 4.04–4.26 (m, 2H, Pip 2,6-H), 7.10 (d, J = 7.9 Hz, 1H, Ph 6-H), 7.16 (s, 1H, Ph 2-H), 7.30 (d, J = 8.0 Hz, 1H, Ph 4-H), 7.37 (t, J = 7.7 Hz, 1H, Ph 5-H), 8.01 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 21.4 (CH₃), 28.6 (C(CH₃)₃), 28.8 (2 × CH₂, Pip 3,5-C), 35.3 (Pip 4-C), 44.3 (2 × CH₂, Pip 2,6-C), 51.4 (OCH₃), 79.6 (C(CH₃)₃), 111.8 (Pyr 4-C), 123.6 (Ph 6-C), 127.4 (Ph 2-C), 129.1 (Ph 5-C), 130.3 (Ph 4-C), 139.4 (Ph 1-C), 139.8 (Ph 3-C), 142.9 (Pyr 3-C), 150.0 (Pyr 5-C), 155.0 (COOC(CH₃)₃), 163.8 (COOCH₃). ¹⁵N-NMR (41 MHz, CDCl₃): δ −159.9 (Pyr N-1), −76.2 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{−1}): 2979, 1703 (C=O), 1688 (C=O), 1243, 779. MS m/z (%): 400 ([M + H]⁺, 100%). HRMS (ESI⁺) for C₂₂H₂₉N₃NaO₄ ([M + Na]⁺) calcd 422.2050, found 422.2050.

3.4.3. *tert*-Butyl

4-[1-(3-fluorophenyl)-4-(methoxycarbonyl)-1H-pyrazol-5-yl]piperidine-1-carboxylate (**5d**)

Compound **3a** was coupled with (3-fluorophenyl)hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:8, *v/v*) to provide compound **5d** as yellowish crystals. Yield 433 mg (73%), mp 134–136 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.45 (s, 9H, C(CH₃)₃), 1.51–1.64 (m, 2H, Pip 3,5-H), 2.27 (qd, J = 12.7 Hz, 4.4 Hz, 2H, Pip 3,5-H), 2.49–2.72 (m, 2H, Pip 2,6-H), 3.08 (tt, J = 12.3 Hz, 3.6 Hz, 1H, Pip 4-H), 3.83 (s, 3H, OCH₃), 3.96–4.32 (m, 2H, Pip 2,6-H), 7.05–7.17 (m, 2H, Ph 2,6-H), 7.19–7.25 (m, 1H, Ph 4-H), 7.43–7.53 (m, 1H, Ph 5-H), 8.02 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 28.8 (2 × CH₂, Pip 3,5-C), 35.3 (Pip 4-C), 44.3 (2 × CH₂, Pip 2,6-C), 51.5 (OCH₃), 79.7 (C(CH₃)₃), 112.3 (Pyr 4-C), 114.6 (d, J = 23.8 Hz, Ph 2-C), 116.8 (d, J = 20.9 Hz, Ph 4-C), 122.5 (d, J = 3.3 Hz, Ph 6-C), 130.7 (d, J = 9.0 Hz, Ph 5-C), 140.7 (d, J = 9.7 Hz, Ph 1-C), 143.3 (Pyr 3-C), 150.1 (Pyr 5-C), 154.9 (COOC(CH₃)₃), 162.8 (d, J = 249.7 Hz, Ph 3-C), 163.5 (COOCH₃). ¹⁵N-NMR (41 MHz, CDCl₃): δ −161.2 (Pyr N-1), −74.5 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{−1}): 2980, 1711 (C=O), 1674 (C=O), 1243, 867. MS m/z (%): 404 ([M + H]⁺, 99%). HRMS (ESI⁺) for C₂₁H₂₆FN₃NaO₄ ([M + Na]⁺) calcd 426.1800, found 426.1799.

3.4.4. *tert*-Butyl

4-[1-(2-fluorophenyl)-4-(methoxycarbonyl)-1H-pyrazol-5-yl]piperidine-1-carboxylate (**5e**)

Compound **3a** was coupled with (2-fluorophenyl)hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:8, *v/v*) to provide compound **5e** as yellowish crystals. Yield 367 mg (62%), mp 114–116 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.43 (s, 9H, C(CH₃)₃), 1.48–1.58 (m, 1H, Pip 3-H), 1.60–1.76 (m, 1H, Pip 5-H), 2.03–2.30 (m, 2H, Pip 3,5-H), 2.44–2.71 (m, 2H, Pip 2,6-H), 2.88–3.05 (m, 1H, Pip 4-H), 3.83 (s, 3H, OCH₃), 3.95–4.29 (m, 2H, Pip 2,6-H), 7.22–7.32 (m, 2H, Ph 3,6-H), 7.34–7.42 (m, 1H, Ph 5-H), 7.47–7.55 (m, 1H, Ph 4-H), 8.06 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃ and 2 × CH₂, Pip 3,5-C), 35.6 (Pip 4-C), 44.1 (2 × CH₂, Pip 2,6-C), 51.4 (OCH₃), 79.6 (C(CH₃)₃), 111.8 (Pyr 4-C), 116.9 (d, J = 19.6 Hz, Ph 3-C), 125.0 (d, J = 4.0 Hz, Ph 6-C), 127.4 (d, J = 12.6 Hz, Ph 1-C), 129.7 (Ph 5-C), 131.8 (d, J = 7.7 Hz, Ph 4-C), 143.7 (Pyr 3-C), 151.4 (Pyr 5-C), 154.9 (COOC(CH₃)₃), 157.5 (d, J = 252.5 Hz, Ph 2-C), 163.6 (COOCH₃). ¹⁵N-NMR (41 MHz, CDCl₃): δ −292.8 (N-Boc), −172.7 (Pyr N-1), −73.8 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{−1}): 2980, 1716 (C=O), 1682 (C=O), 1275, 770. MS m/z (%): 404 ([M + H]⁺, 96%). HRMS (ESI⁺) for C₂₁H₂₆FN₃NaO₄ ([M + Na]⁺) calcd 426.1800, found 426.1800.

3.4.5. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]piperidine-1-carboxylate (**5f**)

Compound **3a** was coupled with (4-methoxyphenyl)hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:8, *v/v*) to provide compound **5f** as orange crystals. Yield 366 mg (60%), mp 151–153 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.44 (s, 9H, C(CH₃)₃), 1.48–1.59 (m, 2H, Pip 3,5-H), 2.20 (qd, J = 12.7 Hz, 5.1 Hz, 2H, Pip 3,5-H), 2.49–2.73 (m, 2H, Pip 2,6-H), 3.09 (tt, J = 12.4 Hz,

3.6 Hz, 1H, Pip 4-H), 3.83 (s, 3H, COOCH₃), 3.87 (s, 3H, OCH₃), 3.99–4.30 (m, 2H, Pip 2,6-H), 6.98 (d, *J* = 8.8 Hz, 2H, Ph 3,5-H), 7.23 (d, *J* = 8.8 Hz, 2H, Ph 2,6-H), 7.99 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 28.9 (2 × CH₂, Pip 3,5-C), 35.3 (Pip 4-C), 44.2 (2 × CH₂, Pip 2,6-C), 51.4 (COOCH₃), 55.7 (OCH₃), 79.6 (C(CH₃)₃), 111.6 (Pyr 4-C), 114.5 (2 × CH, Ph 3,5-C), 128.0 (2 × CH, Ph 2,6-C), 132.4 (Ph 1-C), 142.7 (Pyr 3-C), 150.2 (Pyr 5-C), 154.9 (COOC(CH₃)₃), 160.3 (Ph 4-C), 163.8 (COOCH₃). ¹⁵N-NMR (41 MHz, CDCl₃): δ −161.4 (Pyr N-1), −75.4 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{−1}): 2981, 1715 (C=O), 1682 (C=O), 1245, 780. MS *m/z* (%): 416 ([M+H]⁺, 100%). HRMS (ESI⁺) for C₂₂H₂₉N₃NaO₅ ([M+Na]⁺) calcd 438.1999, found 438.2000.

3.4.6. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-yl]piperidine-1-carboxylate (**5g**)

Compound **3a** was coupled with (3-methoxyphenyl)hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:9, *v/v*) to provide compound **5g** as yellowish crystals. Yield 330 mg (54%), mp 69–71 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.45 (s, 9H, C(CH₃)₃), 1.50–1.61 (m, 2H, Pip 3,5-H), 2.27 (qd, *J* = 12.7 Hz, 4.3 Hz, 2H, Pip 3,5-H), 2.51–2.71 (m, 2H, Pip 2,6-H), 3.11 (tt, *J* = 12.4 Hz, 3.7 Hz, 1H, Pip 4-H), 3.83 (s, 6H, OCH₃ and COOCH₃), 3.99–4.29 (m, 2H, Pip 2,6-H), 6.85–6.93 (m, 2H, Ph 2,4-H), 7.00–7.06 (m, 1H, Ph 6-H), 7.35–7.43 (m, 1H, Ph 5-H), 8.01 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 28.8 (2 × CH₂, Pip 3,5-C), 35.3 (Pip 4-C), 44.3 (2 × CH₂, Pip 2,6-C), 51.4 (COOCH₃), 55.7 (OCH₃), 79.6 (C(CH₃)₃), 112.0 (Pyr 4-C), 112.5 (Ph 2-C), 115.5 (Ph 4-C), 118.8 (Ph 6-C), 130.1 (Ph 5-C), 140.4 (Ph 1-C), 143.0 (Pyr 3-C), 150.0 (Pyr 5-C), 155.0 (COOC(CH₃)₃), 160.4 (Ph 3-C), 163.7 (COOCH₃). IR (FT-IR, ν_{max}, cm^{−1}): 2979, 1702 (C=O), 1686 (C=O), 1109, 778. MS *m/z* (%): 400 ([M + H]⁺, 100%). HRMS (ESI⁺) for C₂₂H₂₉N₃NaO₅ ([M + Na]⁺) calcd 438.1999, found 438.2000.

3.4.7. *tert*-Butyl 4-{4-(methoxycarbonyl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl}piperidine-1-carboxylate (**5h**)

Compound **3a** was coupled with [3-(trifluoromethyl)phenyl]hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:5, *v/v*) to provide compound **5h** as yellowish crystals. Yield 506 mg (76%), mp 113–115 °C. ¹H-NMR (700 MHz, CDCl₃): δ 1.46 (s, 9H, C(CH₃)₃), 1.55–1.62 (m, 2H, Pip 3,5-H), 2.24–2.37 (m, 2H, Pip 3,5-H), 2.50–2.70 (m, 2H, Pip 2,6-H), 3.05 (tt, *J* = 12.3 Hz, 3.6 Hz, 1H, Pip 4-H), 3.86 (s, 3H, OCH₃), 4.06–4.29 (m, 2H, Pip 2,6-H), 7.54–7.57 (m, 1H, Ph 6-H), 7.65 (br s, 1H, Ph 2-H), 7.68 (t, *J* = 7.9 Hz, 1H, Ph 5-H), 7.79 (br s, 1H, Ph 4-H), 8.06 (s, 1H, Pyr 3-H). ¹³C-NMR (176 MHz, CDCl₃): δ 28.4 (C(CH₃)₃), 28.8 (2 × CH₂, Pip 3,5-C), 35.4 (Pip 4-C), 44.1 (2 × CH₂, Pip 2,6-C), 51.4 (OCH₃), 79.6 (C(CH₃)₃), 112.5 (Pyr 4-C), 123.3 (q, *J* = 271.5 Hz, CF₃), 123.7 (q, *J* = 3.7 Hz, Ph 2-C), 126.2 (q, *J* = 3.7 Hz, Ph 4-C), 129.7 (Ph 5-C), 130.1 (Ph 6-C), 132.1 (q, *J* = 33.3 Hz, Ph 3-C), 139.8 (Ph 1-C), 143.5 (Pyr 3-C), 150.1 (Pyr 5-C), 154.8 (COOC(CH₃)₃), 163.3 (COOCH₃). ¹⁵N-NMR (71 MHz, CDCl₃): δ −294.7 (N-Boc), −163.3 (Pyr N-1), −76.0 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{−1}): 2980, 1714 (C=O), 1686 (C=O), 1169, 1062. MS *m/z* (%): 354 ([M-Boc + H]⁺), 454 ([M + H]⁺), 99%. HRMS (ESI⁺) for C₂₂H₂₆F₃N₃NaO₄ ([M + Na]⁺) calcd 476.1768, found 476.1768.

3.4.8. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-methyl-1H-pyrazol-5-yl]piperidine-1-carboxylate (**5i**)

Compound **3a** was coupled with methylhydrazine. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:3, *v/v*) to provide compound **5i** as white crystals. Yield 242 mg (51%), mp 147–149 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.48 (s, 9H, C(CH₃)₃), 1.59–1.70 (m, 2H, Pip 3,5-H), 2.15 (qd, *J* = 12.7 Hz, 4.4 Hz, 2H, Pip 3,5-H), 2.68–2.89 (m, 2H, Pip 2,6-H), 3.53 (tt, *J* = 12.6 Hz, 3.7 Hz, 1H, Pip 4-H), 3.79 (s, 3H, OCH₃), 3.90 (s, 3H, CH₃), 4.10–4.44 (m, 2H, Pip 2,6-H), 7.81 (s, 1H, Pyr 3-H). ¹³C NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 28.6 (2 × CH₂, Pip 3,5-C), 34.2 (Pip 4-C), 38.7 (CH₃), 44.5 (2 × CH₂, Pip 2,6-C), 51.2 (OCH₃), 79.8 (C(CH₃)₃), 111.3 (Pyr 4-C), 141.5 (Pyr 3-C), 148.8 (Pyr 5-C), 154.9 (COOC(CH₃)₃), 164.0 (COOCH₃). ¹⁵N NMR (41 MHz, CDCl₃): δ −293.2

(N-Boc), -176.9 (Pyr N-1), -75.1 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{-1}): 2980, 1705 (C=O), 1688 (C=O), 1234, 779. MS m/z (%): 324 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI⁺) for $\text{C}_{16}\text{H}_{25}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 346.1737, found 346.1737.

3.4.9. *tert*-Butyl

(3*R*)-3-[4-(methoxycarbonyl)-1-phenyl-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5j**)

Compound **3b** was coupled with phenylhydrazine. The obtained residue was purified by column chromatography (SiO_2 , eluent: acetone/*n*-hexane, 1:7, *v/v*) to provide compound **5j** as brownish oil. Yield 379 mg (67%), $[\alpha]_{\text{D}}^{20} = 6.4$ (*c* 1.12, MeOH). ¹H-NMR (400 MHz, CDCl_3): δ 1.40 (s, 10H, $\text{C}(\text{CH}_3)_3$ and Pip 5-H), 1.63–1.78 (m, 2H, Pip 4,5-H), 2.46 (qd, *J* = 13.1 Hz, 4.1 Hz, 1H, Pip 4-H), 2.74–2.87 (m, 1H, Pip 6-H), 2.88–3.01 (m, 1H, Pip 3-H), 3.54–3.69 (m, 1H, Pip 2-H), 3.86 (s, 3H, OCH_3), 3.92–4.17 (m, 2H, Pip 2,6-H), 7.36–7.42 (m, 2H, Ph 2,6-H), 7.48–7.54 (m, 3H, Ph 3,4,5-H), 8.05 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl_3): δ 25.3 (Pip 5-C), 27.4 (Pip 4-C), 28.5 ($\text{C}(\text{CH}_3)_3$), 36.0 (Pip 3-C), 43.7 (Pip 6-C), 46.1 (Pip 2-C), 51.5 (OCH_3), 79.6 ($\text{C}(\text{CH}_3)_3$), 112.3 (Pyr 4-C), 126.5 (2 \times CH, Ph 2,6-C), 129.4 (Ph 4-C), 129.5 (2 \times CH, Ph 3,5-C), 139.0 (Ph 1-C), 143.3 (Pyr 3-C), 148.1 (Pyr 5-C), 154.8 ($\text{COOC}(\text{CH}_3)_3$), 163.9 (COOCH_3). ¹⁵N-NMR (41 MHz, CDCl_3): δ -159.4 (Pyr N-1), -76.1 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{-1}): 2975, 1716 (C=O), 1687 (C=O), 1261, 1099, 765. MS m/z (%): 286 ($[\text{M-Boc}+\text{H}]^+$), 386 ($[\text{M} + \text{H}]^+$), 95%. HRMS (ESI⁺) for $\text{C}_{21}\text{H}_{27}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 408.1894, found 408.1893.

3.4.10. *tert*-Butyl

(3*S*)-3-[4-(methoxycarbonyl)-1-phenyl-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5k**)

Compound **3c** was coupled with phenylhydrazine. The obtained residue was purified by column chromatography (SiO_2 , eluent: acetone/*n*-hexane, 1:11, *v/v*) to provide compound **5k** as brownish oil. Yield 436 mg (77%), $[\alpha]_{\text{D}}^{20} = -6.4$ (*c* 0.73, MeOH). ¹H-NMR (400 MHz, CDCl_3): 1.40 (s, 10H, $\text{C}(\text{CH}_3)_3$ and Pip 5-H), 1.60–1.80 (m, 2H, Pip 4,5-H), 2.46 (q, *J* = 13.3 Hz, 1H, Pip 4-H), 2.80 (s, 1H, Pip 6-H), 2.94 (s, 1H, Pip 3-H), 3.48–3.79 (m, 1H, Pip 2-H), 3.86 (s, 3H, OCH_3), 3.91–4.30 (m, 2H, Pip 2,6-H), 7.32–7.46 (m, 2H, Ph 2,6-H), 7.46–7.56 (m, 3H, Ph 3,4,5-H), 8.05 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl_3): δ 25.3 (Pip 5-C), 27.4 (Pip 4-C), 28.5 ($\text{C}(\text{CH}_3)_3$), 36.0 (Pip 3-C), 44.0 (Pip 6-C), 46.0 (Pip 2-C), 51.5 (OCH_3), 79.6 ($\text{C}(\text{CH}_3)_3$), 112.3 (Pyr 4-C), 126.5 (2 \times CH, Ph 2,6-C), 129.4 (Ph 4-C), 129.5 (2 \times CH, Ph 3,5-C), 139.1 (Ph 1-C), 143.3 (Pyr 3-C), 148.1 (Pyr 5-C), 154.7 ($\text{COOC}(\text{CH}_3)_3$), 163.9 (COOCH_3). IR (FT-IR, ν_{\max} , cm^{-1}): 2979, 1717 (C=O), 1684 (C=O), 1408, 1259, 757. MS m/z (%): 386 ($[\text{M} + \text{H}]^+$, 96%). HRMS (ESI⁺) for $\text{C}_{21}\text{H}_{27}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 408.1894, found 408.1892.

3.4.11. *tert*-Butyl

(3*R*)-3-[4-(methoxycarbonyl)-1-(4-methylphenyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5l**)

Compound **3b** was coupled with *p*-tolylhydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO_2 , eluent: acetone/*n*-hexane, 1:7, *v/v*) to provide compound **5l** as brownish oil. Yield 458 mg (78%), $[\alpha]_{\text{D}}^{20} = 4.1$ (*c* 0.62, MeOH). ¹H-NMR (400 MHz, CDCl_3): δ 1.40 (s, 10H, $\text{C}(\text{CH}_3)_3$ and Pip 5-H), 1.61–1.74 (m, 2H, Pip 4,5-H), 2.43 (s, 4H, Pip 4-H and CH_3), 2.79 (s, 1H, Pip 6-H), 2.93 (s, 1H, Pip 3-H), 3.48–3.72 (m, 1H, Pip 2-H), 3.85 (s, 3H, OCH_3), 3.90–4.18 (m, 2H, Pip 2,6-H), 7.22–7.33 (m, 4H, Ph 2,3,5,6-H), 8.03 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl_3): δ 21.4 (CH_3), 25.3 (Pip 5-C), 27.4 (Pip 4-C), 28.5 ($\text{C}(\text{CH}_3)_3$), 36.0 (Pip 3-C), 43.9 (Pip 6-C), 45.8 (Pip 2-C), 51.5 (OCH_3), 79.5 ($\text{C}(\text{CH}_3)_3$), 112.1 (Pyr 4-C), 126.3 (2 \times CH, Ph 2,6-C), 130.0 (2 \times CH, Ph 3,5-C), 136.6 (Ph 1-C), 139.6 (Ph 4-C), 143.1 (Pyr 3-C), 148.1 (Pyr 5-C), 154.7 ($\text{COOC}(\text{CH}_3)_3$), 164.0 (COOCH_3). ¹⁵N-NMR (41 MHz, CDCl_3): δ -157.9 (Pyr N-1), -74.6 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{-1}): 2976, 1710 (C=O), 1692 (C=O), 1148, 824. MS m/z (%): 300 ($[\text{M-Boc} + \text{H}]^+$), 400 ($[\text{M} + \text{H}]^+$), 97%. HRMS (ESI⁺) for $\text{C}_{22}\text{H}_{29}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 422.2050, found 422.2052.

3.4.12. *tert*-Butyl (3*S*)-3-[4-(methoxycarbonyl)-1-(4-methylphenyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5m**)

Compound **3c** was coupled with *p*-tolylhydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:9, *v/v*) to provide compound **5m** as brownish oil. Yield 475 mg (81%), $[\alpha]_{\text{D}}^{20} = -4.3$ (*c* 0.86, MeOH). ¹H-NMR (400 MHz, CDCl₃): δ 1.40 (s, 10H, C(CH₃)₃ and Pip 5-H), 1.61–1.77 (m, 2H, Pip 4,5-H), 2.43 (s, 4H, Pip 4-H and CH₃), 2.79 (s, 1H, Pip 6-H), 2.93 (s, 1H, Pip 3-H), 3.48–3.76 (m, 1H, Pip 2-H), 3.85 (s, 3H, OCH₃), 3.90–4.26 (m, 2H, Pip 2,6-H), 7.21–7.32 (m, 4H, Ph 2,3,5,6-H), 8.03 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 21.4 (CH₃), 25.3 (Pip 5-C), 27.4 (Pip 4-C), 28.5 (C(CH₃)₃), 36.1 (Pip 3-C), 43.5 (Pip 6-C), 46.4 (Pip 2-C), 51.5 (OCH₃), 79.5 (C(CH₃)₃), 112.1 (Pyr 4-C), 126.3 (2 × CH, Ph 2,6-C), 130.0 (2 × CH, Ph 3,5-C), 136.6 (Ph 1-C), 139.6 (Ph 4-C), 143.1 (Pyr 3-C), 148.1 (Pyr 5-C), 154.7 (COOC(CH₃)₃), 164.0 (COOCH₃). IR (FT-IR, ν_{max}, cm⁻¹): 2930, 1714 (C=O), 1688 (C=O), 1261, 822. MS *m/z* (%): 400 ([M + H]⁺, 95%). HRMS (ESI⁺) for C₂₂H₂₉N₃NaO₄ ([M + Na]⁺) calcd 422.2050, found 422.2051.

3.4.13. *tert*-Butyl (3*R*)-3-[4-(methoxycarbonyl)-1-[3-(trifluoromethyl)phenyl]-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5n**)

Compound **3b** was coupled with [3-(trifluoromethyl)phenyl]hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:5, *v/v*) to provide compound **5n** as brownish oil. Yield 526 mg (79%), $[\alpha]_{\text{D}}^{20} = 9.9$ (*c* 1.31, MeOH). ¹H-NMR (700 MHz, CDCl₃): δ 1.39 (br s, 10H, C(CH₃)₃ and Pip 5-H), 1.68–1.77 (m, 2H, Pip 4,5-H), 2.50 (qd, *J* = 12.9 Hz, 3.9 Hz, 1H, Pip 4-H), 2.72–3.00 (m, 2H, Pip 3,6-H), 3.52–3.75 (m, 1H, Pip 2-H), 3.87 (s, 3H, OCH₃), 3.90–4.21 (m, 2H, Pip 2,6-H), 7.52–7.69 (m, 2H, Ph 5,6-H), 7.71 (br s, 1H, Ph 2-H), 7.73–7.82 (m, 1H, Ph 4-H), 8.07 (s, 1H, Pyr 3-H). ¹³C-NMR (176 MHz, CDCl₃): δ 25.2 (Pip 5-C), 27.3 (Pip 4-C), 28.3 (C(CH₃)₃), 35.9 (Pip 3-C), 43.9 (Pip 6-C), 45.7 (Pip 2-C), 51.5 (OCH₃), 79.6 (C(CH₃)₃), 112.8 (Pyr 4-C), 123.3 (q, *J* = 272.4 Hz, CF₃), 123.5 (Ph 2-C), 126.1 (Ph 4-C), 129.4 (Ph 5-C), 130.0 (Ph 6-C), 132.2 (Ph 3-C), 139.3 (Ph 1-C), 143.7 (Pyr 3-C), 148.1 (Pyr 5-C), 154.7 (COOC(CH₃)₃), 163.5 (COOCH₃). ¹⁵N-NMR (41 MHz, CDCl₃): δ -162.0 (Pyr N-1), -76.1 (Pyr N-2). IR (FT-IR, ν_{max}, cm⁻¹): 2951, 1717 (C=O), 1688 (C=O), 1130, 1098. MS *m/z* (%): 354 ([M-Boc + H]⁺), 454 ([M + H]⁺), 96%. HRMS (ESI⁺) for C₂₂H₂₆F₃N₃NaO₄ ([M + Na]⁺) calcd 476.1768, found 476.1769.

3.4.14. *tert*-Butyl (3*S*)-3-[4-(methoxycarbonyl)-1-[3-(trifluoromethyl)phenyl]-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**5o**)

Compound **3c** was coupled with [3-(trifluoromethyl)phenyl]hydrazine hydrochloride. The obtained residue was purified by column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:11, *v/v*) to provide compound **5o** as brownish oil. Yield 420 mg (63%), $[\alpha]_{\text{D}}^{20} = -9.8$ (*c* 0.85, MeOH). ¹H-NMR (700 MHz, CDCl₃): δ 1.39 (br s, 10H, C(CH₃)₃ and Pip 5-H), 1.68–1.77 (m, 2H, Pip 4,5-H), 2.50 (qd, *J* = 12.9 Hz, 3.9 Hz, 1H, Pip 4-H), 2.72–3.00 (m, 2H, Pip 3,6-H), 3.52–3.75 (m, 1H, Pip 2-H), 3.87 (s, 3H, OCH₃), 3.90–4.21 (m, 2H, Pip 2,6-H), 7.52–7.69 (m, 2H, Ph 5,6-H), 7.71 (br s, 1H, Ph 2-H), 7.73–7.82 (m, 1H, Ph 4-H), 8.08 (s, 1H, Pyr 3-H). ¹³C-NMR (176 MHz, CDCl₃): δ 25.2 (Pip 5-C), 27.3 (Pip 4-C), 28.3 (C(CH₃)₃), 35.9 (Pip 3-C), 43.9 (Pip 6-C), 45.7 (Pip 2-C), 51.5 (OCH₃), 79.6 (C(CH₃)₃), 112.8 (Pyr 4-C), 123.3 (q, *J* = 272.4 Hz, CF₃), 123.5 (Ph 2-C), 126.1 (Ph 4-C), 129.4 (Ph 5-C), 130.0 (Ph 6-C), 132.2 (Ph 3-C), 139.3 (Ph 1-C), 143.7 (Pyr 3-C), 148.1 (Pyr 5-C), 154.7 (COOC(CH₃)₃), 163.5 (COOCH₃). IR (FT-IR, ν_{max}, cm⁻¹): 2951, 1717 (C=O), 1688 (C=O), 1130, 1099. MS *m/z* (%): 454 ([M + H]⁺, 100%). HRMS (ESI⁺) for C₂₂H₂₆F₃N₃NaO₄ ([M + Na]⁺) calcd 476.1768, found 476.1772.

3.5. Synthesis of *tert*-Butyl 4-[4-(methoxycarbonyl)-1*H*-pyrazolyl]piperidine-1-carboxylate (**7**)

Compound **3a** (500 mg, 1.5 mmol) was dissolved in EtOH (15 mL) and treated with 55% hydrazine hydrate solution (74 mg, 1.5 mmol). Reaction mixture was stirred at r.t. for 18 h. After removal of the solvent in vacuo, the residue was purified by flash column chromatography (SiO₂, eluent: acetone/*n*-hexane, 1:7, *v/v*) to provide compound **7** as white crystals.

Yield 272 mg (60%), mp 128–130 °C. $^1\text{H-NMR}$ (700 MHz, CDCl_3): δ 1.47 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.64–1.78 (m, 2H, Pip 3,5-H), 1.92–1.99 (m, 2H, Pip 3,5-H), 2.77–2.95 (m, 2H, Pip 2,6-H), 3.53 (t, $J = 12.0$ Hz, 1H, Pip 4-H), 3.83 (s, 3H, OCH_3), 4.10–4.36 (m, 2H, Pip 2,6-H), 7.96 (s, 1H, Pyr 3(5)-H), 11.52 (s, 1H, Pyr NH). $^{13}\text{C-NMR}$ (176 MHz, CDCl_3): δ 28.5 ($\text{C}(\text{CH}_3)_3$), 30.8 ($2 \times \text{CH}_2$, Pip 3,5-C), 33.8 (Pip 4-C), 44.2 ($2 \times \text{CH}_2$, Pip 2,6-C), 51.2 (OCH_3), 79.8 ($\text{C}(\text{CH}_3)_3$), 110.1 (Pyr 4-C), 138.7 and 153.6 (Pyr 3(5)-C), 154.9 ($\text{COOC}(\text{CH}_3)_3$), 164.1 (COOCH_3). $^{15}\text{N-NMR}$ (71 MHz, CDCl_3): δ -292.7 (N-Boc). IR (FT-IR, ν_{max} , cm^{-1}): 3208 (N-H), 2980, 1706 (C=O), 1655 (C=O), 1434, 1165, 763. MS m/z (%): 210 ($[\text{M-Boc} + \text{H}]^+$) 308 ($[\text{M} - \text{H}]^-$), 97%. HRMS (ESI $^+$) for $\text{C}_{15}\text{H}_{23}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 332.1581, found 332.1581.

3.6. Synthesis of *tert*-Butyl 4-[4-(methoxycarbonyl)-1H-pyrazolyl]piperidine-1-carboxylates (**5i**, **6i**, **8**)

A solution of compound **7** (100 mg, 0.3 mmol), KOH (27 mg, 0.5 mmol), and alkyl iodide (1 mmol) in DMF (0.75 mL) was stirred at r.t. for 4 h. The reaction mixture was diluted with EtOAc (10 mL), washed with H_2O (2×15 mL) and brine (15 mL). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using an eluent—Hex/ Me_2CO in the appropriate ratio.

3.6.1. *tert*-Butyl

4-[4-(methoxycarbonyl)-1-methyl-1H-pyrazol-3-yl]piperidine-1-carboxylate (**6i**) and *tert*-Butyl 4-[4-(methoxycarbonyl)-1-methyl-1H-pyrazol-5-yl]piperidine-1-carboxylate (**5i**)

Compound **7** was coupled with iodomethane. The obtained residue was purified by column chromatography (SiO_2 , eluent: acetone/*n*-hexane, 1:4, v/v) to provide an inseparable mixture of regioisomers **6i**:**5i** (5:1) as white crystals. Yield 77 mg (74%). $^1\text{H-NMR}$ (700 MHz, CDCl_3) (two isomers are seen in the spectra ratio $\sim 5:1$ (**6i**:**5i**)): δ 1.44 (s, 9H, $\text{C}(\text{CH}_3)_3$, (**6i**)), 1.47 (s, 9H, $\text{C}(\text{CH}_3)_3$, (**5i**)), 1.59–1.76 (m, 2H, Pip 3,5-H, (**6i** and **5i**)), 1.82–1.95 (m, 2H, Pip 3,5-H, (**6i**)), 2.14 (qd, $J = 12.7$ Hz, 4.5 Hz, 2H, Pip 3,5-H, (**5i**)), 2.69–2.95 (m, 2H, Pip 2,6-H, (**6i** and **5i**)), 3.36 (tt, $J = 11.8$ Hz, 3.6 Hz, 1H, Pip 4-H, (**6i**)), 3.54 (t, $J = 12.6$ Hz, 1H, Pip 4-H, (**5i**)), 3.79 (s, 3H, OCH_3 , (**6i**)), 3.80 (s, 3H, OCH_3 , (**5i**)), 3.85 (s, 3H, CH_3 , (**6i**)), 3.92 (s, 3H, CH_3 , (**5i**)), 4.03–4.34 (m, 2H, Pip 2,6-H, (**6i** and **5i**)), 7.78 (s, 1H, Pyr 5-H, (**6i**)), 7.82 (s, 1H, Pyr 3-H, (**5i**)). $^{13}\text{C-NMR}$ (176 MHz, CDCl_3): δ 28.6 ($2 \times \text{CH}_2$, Pip 3,5-C, (**5i**)), 28.6 ($\text{C}(\text{CH}_3)_3$, (**6i** and **5i**)), 31.2 ($2 \times \text{CH}_2$, Pip 3,5-C, (**6i**)), 34.1 (Pip 4-C, (**5i**)), 34.8 (Pip 4-C, (**6i**)), 38.7 (CH_3 , (**5i**)), 39.2 (CH_3 , (**6i**)), 43.8 ($2 \times \text{CH}_2$, Pip 2,6-C, (**6i**)), 44.7 ($2 \times \text{CH}_2$, Pip 2,6-C, (**5i**)), 51.2 (OCH_3 , (**6i**)), 51.2 (OCH_3 , (**5i**)), 79.3 ($\text{C}(\text{CH}_3)_3$, (**6i**)), 79.8 ($\text{C}(\text{CH}_3)_3$, (**5i**)), 110.7 (Pyr 4-C, (**6i**)), 111.3 (Pyr 4-C, (**5i**)), 134.6 (Pyr 5-C, (**6i**)), 141.4 (Pyr 3-C, (**5i**)), 148.7 (Pyr 5-C, (**5i**)), 154.8 ($\text{COOC}(\text{CH}_3)_3$, (**6i**)), 154.9 ($\text{COOC}(\text{CH}_3)_3$, (**5i**)), 158.1 (Pyr 3-C, (**6i**)), 163.9 (COOCH_3 , (**6i**)), 164.0 (COOCH_3 , (**5i**)). $^{15}\text{N-NMR}$ (71 MHz, CDCl_3): δ -294.3 (N-Boc, (**5i**)), -183.8 (Pyr N-1, (**6i**)), -178.3 (Pyr N-1, (**5i**)), -77.3 (Pyr N-2, (**6i**)), -76.7 (Pyr N-2, (**5i**)). MS m/z (%): 324 ($[\text{M} + \text{H}]^+$, 100%). HRMS (ESI $^+$) for $\text{C}_{16}\text{H}_{25}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 346.1737, found 346.1737.

3.6.2. *tert*-Butyl

4-[1-ethyl-4-(methoxycarbonyl)-1H-pyrazol-3-yl]piperidine-1-carboxylate (**8**)

Compound **7** was coupled with iodoethane. The obtained residue was purified by column chromatography (SiO_2 , eluent: acetone/*n*-hexane, 1:5, v/v) to provide compound **8** as white crystals, yield 95 mg (87%), mp 77–78 °C. $^1\text{H-NMR}$ (700 MHz, CDCl_3): δ 1.43–1.50 (m, 12H, $\text{C}(\text{CH}_3)_3$ and CH_2CH_3), 1.72 (qd, $J = 12.5$ Hz, 4.1 Hz, 2H, Pip 3,5-H), 1.85–1.93 (m, 2H, Pip 3,5-H), 2.80–2.90 (m, 2H, Pip 2,6-H), 3.37 (tt, $J = 11.8$ Hz, 3.6 Hz, 1H, Pip 4-H), 3.79 (s, 3H, OCH_3), 4.08–4.23 (m, 4H, Pip 2,6-H and CH_2CH_3), 7.82 (s, 1H, Pyr 5-H). $^{13}\text{C-NMR}$ (176 MHz, CDCl_3): δ 15.2 (CH_2CH_3), 28.6 ($\text{C}(\text{CH}_3)_3$), 31.1 ($2 \times \text{CH}_2$, Pip 3,5-C), 34.9 (Pip 4-C), 44.4 ($2 \times \text{CH}_2$, Pip 2,6-C), 47.3 (CH_2CH_3), 51.3 (OCH_3), 79.9 ($\text{C}(\text{CH}_3)_3$), 110.5 (Pyr 4-C), 133.1 (Pyr 5-C), 155.2 ($\text{COOC}(\text{CH}_3)_3$), 157.8 (Pyr 3-C), 163.9 (COOCH_3). $^{15}\text{N-NMR}$ (71 MHz, CDCl_3): δ -168.7 (Pyr N-1), -82.9 (Pyr N-2). IR (FT-IR, ν_{max} , cm^{-1}): 2980, 1715 (C=O), 1678 (C=O), 1219, 768. MS m/z (%): 338 ($[\text{M} + \text{H}]^+$, 99%). HRMS (ESI $^+$) for $\text{C}_{17}\text{H}_{27}\text{N}_3\text{NaO}_4$ ($[\text{M} + \text{Na}]^+$) calcd 360.1894, found 360.1894.

3.7. Synthesis of 5-[1-(*tert*-Butoxycarbonyl)piperidinyl]-1*H*-pyrazole-4-carboxylic acids (9a–c)

Corresponding ester (**5a**, **5j**, **5k**) (300 mg, 0.78 mmol) was dissolved in MeOH (0.1 mM) and treated with 2 N NaOH (4 equiv). The solution was stirred under reflux for 5 h. After removal of the solvent in vacuo, the residue was dissolved in water (15 mL), washed with EtOAc (2 × 15 mL), acidified with 1 M KHSO₄ (pH = 1), and washed with EtOAc (2 × 15 mL). The extracts were combined and dried over sodium sulfate, filtered, and concentrated to dryness to give desired compounds which were directly used in the next step without further purification.

3.7.1. 5-[1-(*tert*-Butoxycarbonyl)piperidin-4-yl]-1-phenyl-1*H*-pyrazole-4-carboxylic Acid (**9a**)

Brownish crystals, yield 240 mg (83%), mp 190–192 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.46 (s, 9H, C(CH₃)₃), 1.52–1.70 (m, 2H, Pip 3,5-H), 2.26 (qd, *J* = 12.7 Hz, 4.3 Hz, 2H, Pip 3,5-H), 2.48–2.76 (m, 2H, Pip 2,6-H), 3.12 (tt, *J* = 12.5 Hz, 3.6 Hz, 1H, Pip 4-H), 3.97–4.30 (m, 2H, Pip 2,6-H), 7.31–7.38 (m, 2H, Ph 2,6-H), 7.47–7.57 (m, 3H, Ph 3,4,5-H), 8.09 (s, 1H, Pyr 3-H), 9.39 (br s, 1H, OH). ¹³C-NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 28.8 (2 × CH₂, Pip 3,5-C), 35.4 (Pip 4-C), 44.3 (2 × CH₂, Pip 2,6-C), 79.8 (C(CH₃)₃), 111.5 (Pyr 4-C), 126.8 (2 × CH, Ph 2,6-C), 129.5 (2 × CH, Ph 3,5-C), 129.7 (Ph 4-C), 139.3 (Ph 1-C), 143.9 (Pyr 3-C), 150.9 (Pyr 5-C), 155.0 (COOC(CH₃)₃), 168.4 (COOH). ¹⁵N-NMR (41 MHz, CDCl₃): δ –159.6 (Pyr N-1), –75.8 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{–1}): 2852, 1675 (C=O), 1547, 1424, 764. MS *m/z* (%): 370 ([M – H][–], 95%). HRMS (ESI⁺) for C₂₀H₂₅N₃NaO₄ ([M + Na]⁺) calcd 394.1737, found 394.1738.

3.7.2. 5-[(3*R*)-1-(*tert*-Butoxycarbonyl)piperidin-3-yl]-1-phenyl-1*H*-pyrazole-4-carboxylic Acid (**9b**)

Brownish crystals, yield 254 mg (88%), mp 86–88 °C, [α]_D²⁰ = 10.4 (*c* 1.10, MeOH). ¹H-NMR (400 MHz, CDCl₃): δ 1.41 (s, 10H, C(CH₃)₃ and Pip 5-H), 1.60–1.80 (m, 2H, Pip 4,5-H), 2.38–2.52 (m, 1H, Pip 4-H), 2.64–2.86 (m, 1H, Pip 6-H), 2.86–3.13 (m, 1H, Pip 3-H), 3.45–3.75 (m, 1H, Pip 2-H), 3.87–4.23 (m, 2H, Pip 2,6-H), 7.36–7.44 (m, 2H, Ph 2,6-H), 7.49–7.57 (m, 3H, Ph 3,4,5-H), 8.15 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 25.2 (Pip 5-C), 27.4 (Pip 4-C), 28.5 (C(CH₃)₃), 36.1 (Pip 3-C), 43.5 (Pip 6-C), 46.3 (Pip 2-C), 79.7 (C(CH₃)₃), 111.8 (Pyr 4-C), 126.5 (2 × CH, Ph 2,6-C), 129.6 (3 × CH, Ph 3,4,5-C), 138.9 (Ph 1-C), 144.1 (Pyr 3-C), 148.8 (Pyr 5-C), 154.7 (COOC(CH₃)₃), 168.3 (COOH). ¹⁵N-NMR (41 MHz, CDCl₃): δ –158.1 (Pyr N-1), –75.9 (Pyr N-2). IR (FT-IR, ν_{max}, cm^{–1}): 2930, 1686 (C=O), 1412, 1147, 764. MS *m/z* (%): 370 ([M – H][–], 97%). HRMS (ESI⁺) for C₂₀H₂₅N₃NaO₄ ([M + Na]⁺) calcd 394.1737, found 394.1738.

3.7.3. 5-[(3*S*)-1-(*tert*-Butoxycarbonyl)piperidin-3-yl]-1-phenyl-1*H*-pyrazole-4-carboxylic Acid (**9c**)

Yellowish crystals, yield 243 mg (84%), mp 88–90 °C, [α]_D²⁰ = –10.5 (*c* 1.0, MeOH). ¹H-NMR (400 MHz, CDCl₃): δ 1.41 (s, 10H, C(CH₃)₃ and Pip 5-H), 1.62–1.78 (m, 2H, Pip 4,5-H), 2.45 (qd, *J* = 12.7 Hz, 7.3 Hz, 1H, Pip 4-H), 2.68–2.87 (m, 1H, Pip 6-H), 2.92–3.08 (m, 1H, Pip 3-H), 3.46–3.76 (m, 1H, Pip 2-H), 3.87–4.21 (m, 2H, Pip 2,6-H), 7.36–7.45 (m, 2H, Ph 2,6-H), 7.47–7.57 (m, 3H, Ph 3,4,5-H), 8.15 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 25.2 (Pip 5-C), 27.4 (Pip 4-C), 28.5 (C(CH₃)₃), 36.1 (Pip 3-C), 43.5 (Pip 6-C), 46.3 (Pip 2-C), 79.7 (C(CH₃)₃), 111.7 (Pyr 4-C), 126.5 (2 × CH, Ph 2,6-C), 129.6 (3 × CH, Ph 3,4,5-C), 138.9 (Ph 1-C), 144.1 (Pyr 3-C), 148.9 (Pyr 5-C), 154.7 (COOC(CH₃)₃), 168.3 (COOH). IR (FT-IR, ν_{max}, cm^{–1}): 2930, 1687 (C=O), 1412, 1148, 765. MS *m/z* (%): 370 ([M – H][–], 97%). HRMS (ESI⁺) for C₂₀H₂₅N₃NaO₄ ([M + Na]⁺) calcd 394.1737, found 394.1739.

3.8. Synthesis of *tert*-Butyl 3- and 4-[4-(*Phenylcarbamoyl*)-1*H*-pyrazol-5-yl]piperidine-1-carboxylates (**10a–c**)

To a solution of the appropriate pyrazole-4-carboxylic acids (**9a–c**) (200 mg, 0.54 mmol) and DMAP (7 mg, 0.05 mmol) in DCM (0.1 mM) cooled to 0 °C temperature EDC·HCl (114 mg, 0.59 mmol) and aniline (50 mg, 0.54 mmol) were added. The reaction mixture was

left at r.t. for 48 h. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography using an eluent—Hex/Me₂CO (6:1, *v/v*).

3.8.1. *tert*-Butyl

4-[1-phenyl-4-(phenylcarbamoyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**10a**)

White crystals, yield 192 mg (80%), mp 187–189 °C. ¹H-NMR (400 MHz, CDCl₃): δ 1.42 (s, 9H, C(CH₃)₃), 1.55–1.76 (m, 2H, Pip 3,5-H), 2.18–2.33 (m, 2H, Pip 3,5-H), 2.43–2.71 (m, 2H, Pip 2,6-H), 3.15 (tt, *J* = 12.4 Hz, 3.5 Hz, 1H, Pip 4-H), 3.99–4.24 (m, 2H, Pip 2,6-H), 7.10–7.18 (m, 1H, NHPH 4-H), 7.33–7.39 (m, 4H, NHPH 3,5-H and NPh 2,6-H), 7.48–7.54 (m, 3H, NPh 3,4,5-H), 7.54–7.61 (m, 2H, NHPH 2,6-H), 7.67 (s, 1H, NH), 7.90 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 28.6 (C(CH₃)₃), 29.6 (2 × CH₂, Pip 3,5-C), 35.4 (Pip 4-C), 44.3 (2 × CH₂, Pip 2,6-C), 79.6 (C(CH₃)₃), 116.0 (Pyr 4-C), 120.5 (2 × CH, NHPH 2,6-C), 124.6 (NHPH 4-C), 126.8 (2 × CH, NPh 2,6-C), 129.2 (2 × CH, NHPH 3,5-C), 129.5 (2 × CH, NPh 3,5-C), 129.7 (NPh 4-C), 138.0 (NHPH 1-C), 138.9 (Pyr 3-C), 139.6 (NPh 1-C), 149.2 (Pyr 5-C), 154.9 (COOC(CH₃)₃), 161.8 (CONH). ¹⁵N-NMR (41 MHz, CDCl₃): δ −252.4 (NH), −159.8 (Pyr N-1), −76.7 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{−1}): 3390, 1671 (C=O), 1435, 748. MS *m/z* (%): 347 ([M-Boc + H]⁺, 99%). HRMS (ESI⁺) for C₂₆H₃₀N₄NaO₃ ([M + Na]⁺) calcd 469.2210, found 469.2209.

3.8.2. *tert*-Butyl

(3*R*)-3-[1-phenyl-4-(phenylcarbamoyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**10b**)

White crystals, yield 197 mg (82%), mp 199–201 °C, [α]_D²⁰ = −20.1 (*c* 0.87, MeOH). ¹H-NMR (400 MHz, CDCl₃): δ 1.40 (s, 10H, C(CH₃)₃ and Pip 5-H), 1.57–1.70 (m, 1H, Pip 5-H), 1.70–1.83 (m, 1H, Pip 4-H), 2.48 (qd, *J* = 12.9 Hz, 4.0 Hz, 1H, Pip 4-H), 2.69–3.05 (m, 2H, Pip 3,6-H), 3.49–3.81 (m, 1H, Pip 2-H), 3.88–4.24 (m, 2H, Pip 2,6-H), 7.10–7.18 (m, 1H, NHPH 4-H), 7.33–7.45 (m, 4H, NHPH 3,5-H and NPh 2,6-H), 7.46–7.59 (m, 5H, NHPH 2,6-H and NPh 3,4,5-H), 7.72 (s, 1H, NH), 7.92 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 25.2 (Pip 5-C), 27.9 (Pip 4-C), 28.5 (C(CH₃)₃), 36.3 (Pip 3-C), 43.8 (Pip 6-C), 46.6 (Pip 2-C), 79.5 (C(CH₃)₃), 116.5 (Pyr 4-C), 120.6 (2 × CH, NHPH 2,6-C), 124.7 (NHPH 4-C), 126.5 (2 × CH, NPh 2,6-C), 129.3 (2 × CH, NHPH 3,5-C), 129.5 (3 × CH, NPh 3,4,5-C), 137.9 (NHPH 1-C), 139.1 (NPh 1-C), 139.3 (Pyr 3-C), 147.0 (Pyr 5-C), 154.8 (COOC(CH₃)₃), 161.8 (CONH). ¹⁵N-NMR (41 MHz, CDCl₃): δ −252.5 (NH), −158.7 (Pyr N-1), −77.1 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{−1}): 3400 (N-H), 1677 (C=O), 1405, 1137, 751. MS *m/z* (%): 447 ([M + H]⁺, 96%). HRMS (ESI⁺) for C₂₆H₃₀N₄NaO₃ ([M + Na]⁺) calcd 469.2210, found 469.2216. The enantiomeric excess was determined by HPLC with a CHIRAL ART Amylose-SA column, *t*_R = 6.5 min (100%), ee = 100%.

3.8.3. *tert*-Butyl

(3*S*)-3-[1-phenyl-4-(phenylcarbamoyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylate (**10c**)

White crystals, yield 161 mg (67%), mp 199–201 °C, [α]_D²⁰ = 19.9 (*c* 0.70, MeOH). ¹H-NMR (400 MHz, CDCl₃): δ 1.39 (s, 10H, C(CH₃)₃ and Pip 5-H), 1.57–1.67 (m, 1H, Pip 5-H), 1.71–1.80 (m, 1H, Pip 4-H), 2.48 (qd, *J* = 12.8 Hz, 4.0 Hz, 1H, Pip 4-H), 2.69–3.02 (m, 2H, Pip 3,6-H), 3.45–3.83 (m, 1H, Pip 2-H), 3.88–4.20 (m, 2H, Pip 2,6-H), 7.10–7.18 (m, 1H, NHPH 4-H), 7.33–7.44 (m, 4H, NHPH 3,5-H and NPh 2,6-H), 7.46–7.61 (m, 5H, NHPH 2,6-H and NPh 3,4,5-H), 7.75 (s, 1H, NH), 7.92 (s, 1H, Pyr 3-H). ¹³C-NMR (101 MHz, CDCl₃): δ 25.2 (Pip 5-C), 27.9 (Pip 4-C), 28.5 (C(CH₃)₃), 36.3 (Pip 3-C), 43.9 (Pip 6-C), 46.6 (Pip 2-C), 79.5 (C(CH₃)₃), 116.5 (Pyr 4-C), 120.6 (2 × CH, NHPH 2,6-C), 124.6 (NHPH 4-C), 126.5 (2 × CH, NPh 2,6-C), 129.2 (2 × CH, NHPH 3,5-C), 129.5 (3 × CH, NPh 3,4,5-C), 138.0 (NHPH 1-C), 139.1 (NPh 1-C), 139.3 (Pyr 3-C), 147.0 (Pyr 5-C), 154.6 (COOC(CH₃)₃), 161.8 (CONH). ¹⁵N-NMR (41 MHz, CDCl₃): δ −252.4 (NH), −158.6 (Pyr N-1), −77.0 (Pyr N-2). IR (FT-IR, ν_{\max} , cm^{−1}): 3402 (N-H), 1677 (C=O), 1405, 1137, 751. MS *m/z* (%): 347 ([M-Boc + H]⁺), 447 ([M + H]⁺), 99%. HRMS (ESI⁺) for C₂₆H₃₀N₄NaO₃ ([M + Na]⁺) calcd 469.2210, found 469.2210. The enantiomeric excess was determined by HPLC with a CHIRAL ART Amylose-SA column, *t*_R = 6.5 min (1.8% minor enantiomer), *t*_R = 9.2 min (98.2% major enantiomer), ee = 96 %.

4. Conclusions

In summary, we developed a new regioselective process for synthesizing 3- or 5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates as achiral and chiral heterocyclic building blocks. Regioselective synthesis of targeted building blocks was obtained starting from piperidine-4-carboxylic and (*R*)- and (*S*)-piperidine-3-carboxylic acids conversion to the corresponding β -enamino diketones via formation of intermediate β -keto esters. Further investigation of the reaction of β -enamino diketones with various aryl and alkyl hydrazines in various solvents at room temperature proved the regioselective formation of 5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates in ethanol compared to polar aprotic or nonprotic solvents. Regioisomeric 3-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates were obtained by treating β -enamino diketone with hydrazine hydrate and subsequent alkylation of tautomeric 3(5)-substituted NH-pyrazole with alkylhalides. Furthermore, we demonstrated that 5-(*N*-Boc-piperidinyl)-1*H*-pyrazole-4-carboxylates can be successfully applied to the synthesis of *tert*-butyl 3- and 4-[4-(phenylcarbamoyl)-1*H*-pyrazol-5-yl]piperidine-1-carboxylates by basic hydrolysis and the subsequent reaction of obtained carboxylic acids with aniline in the presence of EDC·HCl and DMAP. The structures of all synthesized compounds were confirmed by detailed NMR spectroscopy and HRMS investigations.

Supplementary Materials: The following are available online. Figure S1: $^1\text{H-NMR}$ (700 MHz, CDCl_3) spectrum of compound **4a**, Figure S2: $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) spectrum of compound **4a**, Figure S3: $^1\text{H-}^{15}\text{N}$ HMBC (71 MHz, CDCl_3) spectrum of compound **4a**, Figure S4: HRMS (ESI-TOF) of compound **4a**, Figure S5: $^1\text{H-NMR}$ (700 MHz, CDCl_3) spectrum of compound **5a**, Figure S6: $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) spectrum of compound **5a**, Figure S7: $^1\text{H-}^{15}\text{N}$ HMBC (71 MHz, CDCl_3) spectrum of compound **5a**, Figure S8: HRMS (ESI-TOF) of compound **5a**, Figure S9: $^1\text{H-NMR}$ (700 MHz, CDCl_3) spectrum of compound **6a**, Figure S10: $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) spectrum of compound **6a**, Figure S11: $^1\text{H-}^{15}\text{N}$ HMBC (71 MHz, CDCl_3) spectrum of compound **6a**, Figure S12: HRMS (ESI-TOF) of compound **6a**, Figure S13: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5b**, Figure S14: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5b**, Figure S15: $^1\text{H-}^{15}\text{N}$ HMBC (41 MHz, CDCl_3) spectrum of compound **5b**, Figure S16: HRMS (ESI-TOF) of compound **5b**, Figure S17: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5c**, Figure S18: $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) spectrum of compound **5c**, Figure S19: $^{15}\text{N-NMR}$ (41 MHz, CDCl_3) spectrum of compound **5c**, Figure S20: HRMS (ESI-TOF) of compound **5c**, Figure S21: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5d**, Figure S22: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5d**, Figure S23: $^1\text{H-}^{15}\text{N}$ HMBC (41 MHz, CDCl_3) spectrum of compound **5d**, Figure S24: HRMS (ESI-TOF) of compound **5d**, Figure S25: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5e**, Figure S26: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5e**, Figure S27: $^1\text{H-}^{15}\text{N}$ HMBC (41 MHz, CDCl_3) spectrum of compound **5e**, Figure S28: HRMS (ESI-TOF) of compound **5e**, Figure S29: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5f**, Figure S30: $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) spectrum of compound **5f**, Figure S31: $^{15}\text{N-NMR}$ (41 MHz, CDCl_3) spectrum of compound **5f**, Figure S32: HRMS (ESI-TOF) of compound **5f**, Figure S33: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5g**, Figure S34: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5g**, Figure S35: HRMS (ESI-TOF) of compound **5g**, Figure S36: $^1\text{H-NMR}$ (700 MHz, CDCl_3) spectrum of compound **5h**, Figure S37: $^{13}\text{C-NMR}$ (176 MHz, CDCl_3) spectrum of compound **5h**, Figure S38: $^1\text{H-}^{15}\text{N}$ HMBC (71 MHz, CDCl_3) spectrum of compound **5h**, Figure S39: HRMS (ESI-TOF) of compound **5h**, Figure S40: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5i**, Figure S41: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5i**, Figure S42: $^1\text{H-}^{15}\text{N}$ HMBC (41 MHz, CDCl_3) spectrum of compound **5i**, Figure S43: HRMS (ESI-TOF) of compound **5i**, Figure S44: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5j**, Figure S45: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5j**, Figure S46: $^1\text{H-}^{15}\text{N}$ HMBC (41 MHz, CDCl_3) spectrum of compound **5j**, Figure S47: HRMS (ESI-TOF) of compound **5j**, Figure S48: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5k**, Figure S49: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5k**, Figure S50: HRMS (ESI-TOF) of compound **5k**, Figure S51: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5l**, Figure S52: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5l**, Figure S53: $^1\text{H-}^{15}\text{N}$ HMBC (41 MHz, CDCl_3) spectrum of compound **5l**, Figure S54: HRMS (ESI-TOF) of compound **5l**, Figure S55: $^1\text{H-NMR}$ (400 MHz, CDCl_3) spectrum of compound **5m**, Figure S56: $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) spectrum of compound **5m**, Figure S57: HRMS (ESI-TOF) of compound **5m**, Figure S58: $^1\text{H-NMR}$ (700 MHz, CDCl_3) spectrum of compound **5n**, Figure S59: $^{13}\text{C-NMR}$

(176 MHz, CDCl₃) spectrum of compound **5n**, Figure S60: ¹H-¹⁵N HMBC (41 MHz, CDCl₃) spectrum of compound **5n**, Figure S61: HRMS (ESI-TOF) of compound **5n**, Figure S62: ¹H-NMR (700 MHz, CDCl₃) spectrum of compound **5o**, Figure S63: ¹³C-NMR (176 MHz, CDCl₃) spectrum of compound **5o**, Figure S64: HRMS (ESI-TOF) of compound **5o**, Figure S65: ¹H-NMR (700 MHz, CDCl₃) spectrum of compound **7**, Figure S66: ¹³C-NMR (176 MHz, CDCl₃) spectrum of compound **7**, Figure S67: ¹H-¹H NOESY (CDCl₃) spectrum of compound **7**, Figure S68: HRMS (ESI-TOF) of compound **7**, Figure S69: ¹H-NMR (700 MHz, CDCl₃) spectrum of compounds **6i** and **5i**, Figure S70: ¹³C-NMR (176 MHz, CDCl₃) spectrum of compounds **6i** and **5i**, Figure S71: ¹H-¹⁵N HMBC (71 MHz, CDCl₃) spectrum of compounds **6i** and **5i**, Figure S72: HRMS (ESI-TOF) of compound **6i** and **5i**, Figure S73: ¹H-NMR (700 MHz, CDCl₃) spectrum of compound **8**, Figure S74: ¹³C-NMR (176 MHz, CDCl₃) spectrum of compound **8**, Figure S75: ¹H-¹⁵N HMBC (71 MHz, CDCl₃) spectrum of compound **8**, Figure S76: HRMS (ESI-TOF) of compound **8**, Figure S77: ¹H-NMR (400 MHz, CDCl₃) spectrum of compound **9a**, Figure S78: ¹³C-NMR (101 MHz, CDCl₃) spectrum of compound **9a**, Figure S79: ¹H-¹⁵N HMBC (41 MHz, CDCl₃) spectrum of compound **9a**, Figure S80: HRMS (ESI-TOF) of compound **9a**, Figure S81: ¹H-NMR (400 MHz, CDCl₃) spectrum of compound **9b**, Figure S82: ¹³C-NMR (101 MHz, CDCl₃) spectrum of compound **9b**, Figure S83: ¹H-¹⁵N HMBC (41 MHz, CDCl₃) spectrum of compound **9b**, Figure S84: HRMS (ESI-TOF) of compound **9b**, Figure S85: ¹H-NMR (400 MHz, CDCl₃) spectrum of compound **9c**, Figure S86: ¹³C-NMR (101 MHz, CDCl₃) spectrum of compound **9c**, Figure S87: HRMS (ESI-TOF) of compound **9c**, Figure S88: ¹H-NMR (400 MHz, CDCl₃) spectrum of compound **10a**, Figure S89: ¹³C-NMR (101 MHz, CDCl₃) spectrum of compound **10a**, Figure S90: ¹H-¹⁵N HMBC (41 MHz, CDCl₃) spectrum of compound **10a**, Figure S91: HRMS (ESI-TOF) of compound **10a**, Figure S92: ¹H-NMR (400 MHz, CDCl₃) spectrum of compound **10b**, Figure S93: ¹³C-NMR (101 MHz, CDCl₃) spectrum of compound **10b**, Figure S94: ¹H-¹⁵N HMBC (41 MHz, CDCl₃) spectrum of compound **10b**, Figure S95: HRMS (ESI-TOF) of compound **10b**, Figure S96: ¹H-NMR (400 MHz, CDCl₃) spectrum of compound **10c**, Figure S97: ¹³C-NMR (101 MHz, CDCl₃) spectrum of compound **10c**, Figure S98: ¹H-¹⁵N HMBC (41 MHz, CDCl₃) spectrum of compound **10c**, Figure S99: HRMS (ESI-TOF) of compound **10c**.

Author Contributions: Conceptualization, F.A.S. and A.Š.; methodology, N.K.; validation, N.K., G.M. and G.R.; formal analysis, A.B., G.R. and M.D.; investigation, G.M., V.M. and M.D.; data curation, V.M.; writing—original draft preparation, A.Š., A.B., E.A. and G.M.; writing—review and editing, N.K. and V.K.; visualization A.B., A.Š. and E.A.; resources, F.A.S., supervision, A.Š. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Vipergen ApS (Copenhagen, Denmark).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding authors.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. Singh, P.; Samanta, K.; Das, S.K.; Panda, G. Amino acid chirons: A tool for asymmetric synthesis of heterocycles. *Org. Biomol. Chem.* **2014**, *12*, 6297–6339. [[CrossRef](#)] [[PubMed](#)]
2. Sardina, F.J.; Rapoport, H. Enantiospecific Synthesis of Heterocycles from α -Amino Acids. *Chem. Rev.* **1996**, *96*, 1825–1872. [[CrossRef](#)] [[PubMed](#)]
3. Blaskovich, M.A.T. Unusual Amino Acids in Medicinal Chemistry. *J. Med. Chem.* **2016**, *59*, 10807–10836. [[CrossRef](#)] [[PubMed](#)]
4. Žukauskaitė, A.; Moretto, A.; Peggion, C.; De Zotti, M.; Šačkus, A.; Formaggio, F.; De Kimpe, N.; Mangelinckx, S. Synthesis and Conformational Study of Model Peptides Containing *N*-Substituted 3-Aminoazetidone-3-carboxylic Acids. *Eur. J. Org. Chem.* **2014**, *2014*, 2312–2321. [[CrossRef](#)]
5. Vale, N.; Ferreira, A.; Matos, J.; Fresco, P.; Gouveia, M.J. Amino Acids in the Development of Prodrugs. *Molecules* **2018**, *23*, 2318. [[CrossRef](#)]
6. Bonina, F.P.; Arenare, L.; Palagiano, F.; Saija, A.; Nava, F.A.; Trombetta, D.; De Caprariis, P. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. *J. Pharm. Sci.* **1999**, *88*, 561–567. [[CrossRef](#)]

7. Henzi, V.; Reichling, D.B.; Helm, S.W.; MacDermott, A.B. L-proline activates glutamate and glycine receptors in cultured rat dorsal horn neurons. *Mol. Pharmacol.* **1992**, *41*, 793–801.
8. Wang, M.; Rakesh, K.; Leng, J.; Fang, W.-Y.; Ravindar, L.; Gowda, D.C.; Qin, H.-L. Amino acids/peptides conjugated heterocycles: A tool for the recent development of novel therapeutic agents. *Bioorg. Chem.* **2018**, *76*, 113–129. [[CrossRef](#)]
9. Walsh, C.T.; O'Brien, R.V.; Khosla, C. Nonproteinogenic Amino Acid Building Blocks for Nonribosomal Peptide and Hybrid Polyketide Scaffolds. *Angew. Chem. Int. Ed.* **2013**, *52*, 7098–7124. [[CrossRef](#)]
10. Cerminara, I.; Chiummiento, L.; Funicello, M.; Guarnaccio, A.; Lupattelli, P. Heterocycles in Peptidomimetics and Pseudopeptides: Design and Synthesis. *Pharmaceuticals* **2012**, *5*, 297–316. [[CrossRef](#)]
11. Hollis, S.J. Heterocyclic in Peptide Chemistry. Ph. D. Thesis, The Open University, Milton Keynes, UK, 2000.
12. Kothapalli, Y.; Puthukanoori, R.K.; Alapati, S.R. Enantiospecific first total synthesis of 7a(S)-*p*-hydroxyphenopyrrozin. *Tetrahedron Lett.* **2012**, *53*, 1891–1893. [[CrossRef](#)]
13. Lin, C.-H.; Hong, B.-C.; Lee, G.-H. Asymmetric synthesis of functionalized pyrrolizidines by an organocatalytic and pot-economy strategy. *RSC Adv.* **2016**, *6*, 8243–8247. [[CrossRef](#)]
14. Luna-Freire, K.R.; Scaramal, J.P.S.; Resende, J.A.L.C.; Tormena, C.F.; Oliveira, F.L.; Aparicio, R.; Coelho, F. An asymmetric substrate-controlled Morita–Baylis–Hillman reaction as approach for the synthesis of pyrrolizidinones and pyrrolizidines. *Tetrahedron* **2014**, *70*, 3319–3326. [[CrossRef](#)]
15. Dockerty, P.; Edens, J.G.; Tol, M.B.; Angeles, D.M.; Domenech, A.; Liu, Y.; Hirsch, A.K.H.; Veening, J.-W.; Scheffers, D.-J.; Witte, M.D. Bicyclic enol cyclocarbamates inhibit penicillin-binding proteins. *Org. Biomol. Chem.* **2016**, *15*, 894–910. [[CrossRef](#)]
16. Lu, X.; Shi, L.; Zhang, H.; Jiang, Y.; Ma, D. Assembly of *N*-substituted pyrrolo[2,1-*c*][1,4]benzodiazepine-5,11-diones via copper catalyzed aryl amination. *Tetrahedron* **2010**, *66*, 5714–5718. [[CrossRef](#)]
17. Wang, H.; Jiang, Y.; Gao, K.; Ma, D. Facile synthesis of 1,4-benzodiazepin-3-ones from *o*-bromobenzylamines and amino acids via a cascade coupling/condensation process. *Tetrahedron* **2009**, *65*, 8956–8960. [[CrossRef](#)]
18. Villagordo, J.M.; Heimgartner, H. Synthesis of a novel heterospirocyclic 3-(*N*-methyl-*N*-phenylamino)-2*H*-azirine and its use as an amino acid equivalent in the preparation of a model tripeptide. *Tetrahedron* **1993**, *49*, 7215–7222. [[CrossRef](#)]
19. Heimgartner, H.; Strässler, C.; Linden, A. Synthesis of Tripeptides Containing Heterocyclic α -Amino Acids by Using Heterospirocyclic 3-Amino-2*H*-azirines. *Heterocycles* **2018**, *97*, 333. [[CrossRef](#)]
20. Shimazaki, M.; Hasegawa, J.; Kan, K.; Nomura, K.; Nose, Y.; Kondo, H.; Ohashi, T.; Watanabe, K. Synthesis of captopril starting from an optically active. BETA-hydroxy acid. *Chem. Pharm. Bull.* **1982**, *30*, 3139–3146. [[CrossRef](#)]
21. Luer, M.S.; Rhoney, D.H. Tiagabine: A Novel Antiepileptic Drug. *Ann. Pharmacother.* **1998**, *32*, 1173–1180. [[CrossRef](#)]
22. Leach, J.P.; Brodie, M.J. Tiagabine. *Lancet* **1998**, *351*, 203–207. [[CrossRef](#)]
23. Chorghade, M.S.; Ellegaard, P.; Lee, E.C.; Petersen, H.; Sørensen, P.O. Synthesis of Desmethyl Tiagabine. *Heterocycles* **1994**, *37*, 783. [[CrossRef](#)]
24. Andersen, K.E.; Sørensen, J.L.; Lau, J.; Lundt, B.F.; Petersen, H.; Huusfeldt, P.O.; Suzdak, P.D.; Swedberg, M.D.B. Synthesis of Novel γ -Aminobutyric Acid (GABA) Uptake Inhibitors. 5.1 Preparation and Structure–Activity Studies of Tricyclic Analogues of Known GABA Uptake Inhibitors. *J. Med. Chem.* **2001**, *44*, 2152–2163. [[CrossRef](#)] [[PubMed](#)]
25. Seth, A.; Sharma, P.A.; Tripathi, A.; Choubey, P.K.; Srivastava, P.; Tripathi, P.N.; Shrivastava, S.K. Design, synthesis, evaluation and molecular modeling studies of some novel *N*-substituted piperidine-3-carboxylic acid derivatives as potential anticonvulsants. *Med. Chem. Res.* **2018**, *27*, 1206–1225. [[CrossRef](#)]
26. Schaarschmidt, M.; Höfner, G.; Wanner, K.T. Synthesis and Biological Evaluation of Nipecotinic Acid and Guvacine Derived 1,3-Disubstituted Allenes as Inhibitors of Murine GABA Transporter mGAT1. *ChemMedChem* **2019**, *14*, 1135–1151. [[CrossRef](#)]
27. Saura, J.; Curatolo, L.; Williams, C.E.; Gatti, S.; Benatti, L.; Peeters, C.; Guan, J.; Dragunow, M.; Post, C.; Faull, R.L.M.; et al. Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. *NeuroReport* **1999**, *10*, 161–164. [[CrossRef](#)]
28. Minelli, A.; Conte, C.; Cacciatori, I.; Cornacchia, C.; Pinnen, F. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to l-dopa in a Parkinson's animal model. *Amino Acids* **2012**, *43*, 1359–1367. [[CrossRef](#)]
29. Kanda, T.; Yokosuka, O.; Omata, M. Faldaprevir for the Treatment of Hepatitis C. *Int. J. Mol. Sci.* **2015**, *16*, 4985–4996. [[CrossRef](#)]
30. White, P.W.; Llinàs-Brunet, M.; Amad, M.; Bethell, R.C.; Bolger, G.; Cordingley, M.G.; Duan, J.; Garneau, M.; Lagacé, L.; Thibeault, D.; et al. Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease. *Antimicrob. Agents Chemother.* **2010**, *54*, 4611–4618. [[CrossRef](#)]
31. Bilodeau, F.; Bailey, M.D.; Bhardwaj, P.K.; Bordeleau, J.; Forgione, P.; Garneau, M.; Ghiron, E.; Gorys, V.; Halmos, T.; Jolicoeur, E.S.; et al. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-Arylproline analogs. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 4267–4271. [[CrossRef](#)]
32. Folkers, K.; Enzmann, F.H. Tripeptidine Having the Activity of the Thyrotropin Releasing Hormone. U.S. Patent 3,746,697, 17 July 1973.
33. Ngo, H.T.; Berndt, H.; Wilsdorf, M.; Lentz, D.; Reissig, H.-U. Linear and Cyclic Hybrids of Alternating Thiophene-Amino Acid Units: Synthesis and Effects of Chirality on Conformation and Molecular Packing. *Chem. A Eur. J.* **2013**, *19*, 15155–15165. [[CrossRef](#)]
34. Raja, R.; Hemaiswarya, S.; Ganesan, V.; de Carvalho, I.S. Recent developments in therapeutic applications of Cyanobacteria. *Crit. Rev. Microbiol.* **2015**, *42*, 1–12. [[CrossRef](#)]

35. Shi, B.; Zhou, Y.; Huang, Y.; Zhang, J.; Li, X. Recent advances on the encoding and selection methods of DNA-encoded chemical library. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 361–369. [[CrossRef](#)]
36. Usanov, D.L.; Chan, A.I.; Maianti, J.P.; Liu, D.R. Second-generation DNA-templated macrocycle libraries for the discovery of bioactive small molecules. *Nat. Chem.* **2018**, *10*, 704–714. [[CrossRef](#)]
37. Madsen, D.; Azevedo, C.; Micco, I.; Petersen, L.K.; Vest Hansen, N.J. An overview of DNA-encoded libraries: A versatile tool for drug discovery. *Prog. Med. Chem.* **2020**, *59*, 181–249. [[CrossRef](#)]
38. Blakskjær, P.; Heitner, T.; Vest Hansen, N.J. Fidelity by design: Yoctoreactor and binder trap enrichment for small-molecule DNA-encoded libraries and drug discovery. *Curr. Opin. Chem. Biol.* **2015**, *26*, 62–71. [[CrossRef](#)]
39. Hansen, M.H.; Blakskjær, P.; Petersen, L.K.; Hansen, T.H.; Hojfeldt, J.; Gothelf, K.V.; Vest Hansen, N.J. A Yoctoliter-Scale DNA Reactor for Small-Molecule Evolution. *J. Am. Chem. Soc.* **2009**, *131*, 1322–1327. [[CrossRef](#)]
40. Galloway, W.R.; Isidro-Llobet, A.; Spring, D.R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. *Nat. Commun.* **2010**, *1*, 80. [[CrossRef](#)]
41. Petersen, L.K.; Blakskjær, P.; Chaikuad, A.; Christensen, A.; Dietvorst, J.; Holmkvist, J.; Knapp, S.; Korinek, M.; Larsen, L.K.; Pedersen, A.; et al. Novel p38 α MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library. *MedChemComm* **2016**, *7*, 1332–1339. [[CrossRef](#)]
42. Iškauskienė, M.; Ragaitė, G.; Sløk, F.A.; Šačkus, A. Facile synthesis of novel amino acid-like building blocks by *N*-alkylation of heterocyclic carboxylates with *N*-Boc-3-iodoazetidine. *Mol. Divers.* **2020**, *24*, 1235–1251. [[CrossRef](#)]
43. Malinauskienė, V.; Kveselytė, A.; Dzedulionytė, K.; Bieliauskas, A.; Burinskas, S.; Sløk, F.A.; Šačkus, A. L-Proline and related chiral heterocyclic amino acids as scaffolds for the synthesis of functionalized 2-amino-1,3-selenazole-5-carboxylates. *Chem. Heterocycl. Compd.* **2018**, *54*, 469–473. [[CrossRef](#)]
44. Sackus, A.; Kveselyte, A.; Malinauskiene, V.; Dzedulionyte, K.; Bieliauskas, A.; Burinskas, S.; Krikstolaityte, S.; Slok, F.A. Heterocyclic amino acids as scaffolds for the synthesis of functionalized chiral 1,3-thiazole and 1,3-selenazole derivatives. In Proceedings of the 256th National Meeting and Exposition of the American-Chemical-Society (ACS), Boston, MA, USA, 19–23 August 2018; p. 586.
45. Fustero, S.; Sánchez-Roselló, M.; Barrio, P.; Fuentes, A.S. From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of Pyrazoles. *Chem. Rev.* **2011**, *111*, 6984–7034. [[CrossRef](#)] [[PubMed](#)]
46. Karrouchi, K.; Radi, S.; Ramli, Y.; Taoufik, J.; Mabkhot, Y.N.; Al-Aizari, F.A.; Ansar, M. Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. *Molecules* **2018**, *23*, 134. [[CrossRef](#)] [[PubMed](#)]
47. Ansari, A.; Ali, A.; Asif, M.; Shamsuzzaman, S. Review: Biologically active pyrazole derivatives. *New J. Chem.* **2016**, *41*, 16–41. [[CrossRef](#)]
48. Souza, T.F.; Silva, M.J.V.; Silva, R.G.M.; Gonçalves, D.S.; Simon, P.A.; Jacomini, A.P.; Basso, E.A.; Moura, S.; Martins, M.A.P.; Back, D.F.; et al. Regiochemical Control of Pyrazoles by Solvent and β -Enamino Diketone Structure: Regioselective Synthesis of 4,5-Disubstituted *N*-Phenylpyrazoles. *Asian J. Org. Chem.* **2017**, *6*, 627–633. [[CrossRef](#)]
49. Gao, W.; Lau, T.; Pan, S.; Phillips, D.P.; Wang, X. Compounds and Compositions as TGR5 Agonists. WO Patent WO2012/082947A1, 14 December 2011.
50. Brooks, D.W.; Lu, L.D.-L.; Masamune, S. C-Acylation under Virtually Neutral Conditions. *Angew. Chem. Int. Ed.* **1979**, *18*, 72–74. [[CrossRef](#)]
51. Thomassigny, C.; Le Bouc, G.; Greck, C. Asymmetric syntheses of functionalized pyrrolizidin-3-ones. *Arkivoc* **2012**, *2012*, 231. [[CrossRef](#)]
52. Semenov, V.; Samultsev, D.O.; Krivdin, L.B. Substitution effects in the ^{15}N NMR chemical shifts of heterocyclic azines evaluated at the GIAO-DFT level. *Magn. Reson. Chem.* **2018**, *56*, 767–774. [[CrossRef](#)]
53. Chernyshev, K.A.; Semenov, V.A.; Krivdin, L.B. Quantum-chemical calculations of NMR chemical shifts of organic molecules: VIII. Solvation effects on ^{15}N NMR chemical shifts of nitrogen-containing heterocycles. *Russ. J. Org. Chem.* **2013**, *49*, 379–383. [[CrossRef](#)]
54. Claramunt, R.M.; López, C.; Maria, M.D.S.; Sanz, D.; Elguero, J. The Use of NMR Spectroscopy to Study Tautomerism. *ChemInform* **2007**, *38*, 169–206. [[CrossRef](#)]
55. Secrieru, A.; O'Neill, P.M.; Cristiano, M.L.S. Revisiting the Structure and Chemistry of 3(5)-Substituted Pyrazoles. *Molecules* **2019**, *25*, 42. [[CrossRef](#)]
56. Arbačiauskienė, E.; Krikstolaitytė, S.; Mitrulevičienė, A.; Bieliauskas, A.; Martynaitis, V.; Bechmann, M.; Roller, A.; Šačkus, A.; Holzer, W. On the Tautomerism of *N*-Substituted Pyrazolones: 1,2-Dihydro-3*H*-pyrazol-3-ones versus 1*H*-Pyrazol-3-ols. *Molecules* **2018**, *23*, 129. [[CrossRef](#)]
57. Aguilar-Parrilla, F.; Cativiela, C.; Diaz-De-Villegas, M.D.; Limbach, H.-H.; Smith, J.A.S.; Toiron, C. The tautomerism of 3(5)-phenylpyrazoles: An experimental (^1H , ^{13}C , ^{15}N NMR and X-ray crystallography) study. *J. Chem. Soc. Perkin Trans. 2* **1992**, *2*, 1737–1742. [[CrossRef](#)]
58. Tarabová, D.; Šoralová, S.; Breza, M.; Fronc, M.; Holzer, W.; Milata, V. Use of activated enol ethers in the synthesis of pyrazoles: Reactions with hydrazine and a study of pyrazole tautomerism. *Beilstein J. Org. Chem.* **2014**, *10*, 752–760. [[CrossRef](#)]
59. Huang, A.; Wo, K.; Lee, S.Y.C.; Kneitschel, N.; Chang, J.; Zhu, K.; Mello, T.; Bancroft, L.; Norman, N.J.; Zheng, S.-L. Regioselective Synthesis, NMR, and Crystallographic Analysis of *N*1-Substituted Pyrazoles. *J. Org. Chem.* **2017**, *82*, 8864–8872. [[CrossRef](#)]

60. Liu, X.; Qiao, L.; Zhai, Z.; Cai, P.; Cantrell, C.L.; Tan, C.; Weng, J.; Han, L.; Wu, H. Novel 4-pyrazole carboxamide derivatives containing flexible chain motif: Design, synthesis and antifungal activity. *Pest. Manag. Sci.* **2019**, *75*, 2892–2900. [[CrossRef](#)]
61. Gewehr, M.; Dietz, J.; Grote, T.; Blettner, C.; Grammenos, W.; Hüniger, U.; Müller, B.; Schieweck, F.; Schwögler, A.; Lohmann, J.K.; et al. Pyrazole Carboxylic Acid Anilides, Method for the Production Thereof and Agents Containing Them for Controlling Pathogenic Fungi. WO Patent WO2006087343A1, 15 February 2006.
62. Braun, S.; Kalinowski, H.O.; Berger, S. *150 and more Basic NMR Experiments: A Practical Course*, 2nd ed.; ACS: New York, NY, USA, 2000.
63. Buevich, A.V.; Williamson, R.T.; Martin, G.E. NMR Structure Elucidation of Small Organic Molecules and Natural Products: Choosing ADEQUATE vs HMBC. *J. Nat. Prod.* **2014**, *77*, 1942–1947. [[CrossRef](#)]